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Obesity is an epidemic in many developed nations and maternal obesity can result in 
developmental alterations in offspring that have long-lasting effects.  Two experiments 
were conducted to determine the impact of maternal obesity on placental development 
and early embryonic growth and muscle development.  Experiment one utilized obese 
Lethal Yellow (LY) and normal weight C57BL/6 (B6) dams to assess how maternal 
obesity alters skeletal muscle development in mid-gestational embryos.  Embryos from 
LY dams exhibited decreased embryo and placental weights as well as an increase in the 
myogenic marker desmin.  Furthermore, the adipogenic marker PPARG expression was 
predominately localized to the neural tube and was significantly decreased in LY-derived 
embryos.  The objective of experiment 2 was to identify how maternal obesity alters 
placenta development and function and may be associated with altered development of 
the fetus.  The same mid-gestation embryos and corresponding placenta from LY and B6 
dams were used.  Placenta from LY dams were smaller than when developed in a B6 dam 
and exhibited a phenotype of reduced function.  The placenta also displayed increased 
hypoxia markers and decreased gene expression of enzymes which regulate the transfer 
of active glucocorticoids from the mother to developing embryo.  Interestingly, the 
embryos reared in an obese dam possessed decreased expression of vasculature markers.  
In summary, these experiments support the following findings: (1) maternal obesity 
decreases embryonic and placental weight and results in altered temporal regulation of 
myogenesis; (2) PPARG expression is localized to the neural tube and decreased in LY-
derived embryos indicating a function for this transcription factor in neural tube 
development and suggesting that obesity alters this function; (3) placenta from an obese 
dam display increased hypoxemia and altered glucocorticoid metabolism resulting in 
altered embryonic vasculature and potentially differences in the function of various organ 
systems.  These data represent an important shift in understanding how maternal obesity 
reduces skeletal muscle density during development and its long-term effects on the 
metabolic health of their children. 
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CHAPTER I 
LITERATURE REVIEW 
Incidence of Maternal Obesity and its Correlation to Childhood Obesity 
There has been a rapid rise in the incidence of obesity due to changes in diet and 
activity levels of individuals.  The body mass index (BMI), which is directly correlated 
with the amount of body fat, is the measure used to determine if one is obese.  In order to 
calculate BMI, an individual’s weight in pounds is divided by their height in inches 
squared and multiplied by a conversion factor of 703.  When an adult has a BMI between 
25 and 29.9 they are considered overweight, while an adult with a BMI of 30 or higher is 
considered obese (1).  Obesity worldwide now exists at a prevalence of 15–20% (2).  In 
2011, 27.8% of the total USA population had a BMI greater than 30 (3) while in the UK, 
~25% of the adult population is classified as obese (4).  Bays et al. (5) reported that in the 
USA for the past 20-30 years the rate of overweight or obesity has increased from 15 to 
33% in adults, 5 to 14% in children (2-5 years), 7 to 19% in children (6-11 years), and 5 
to 17% in adolescents (12-19 years).  Due to the increased incidence of obesity, it is now 
considered a significant public health problem which is associated with a reduction in life 
expectancy of ~8 years (4) and is attributed to 2-7 % of the total health care costs in the 
USA (2).  Obesity also has been shown to increase the risk of developing metabolic 
syndrome which comprises several major diseases including type 2 diabetes and coronary 
artery disease (4).   
Overweight and obese women are more likely to gain excessive gestational 
weight and maintain higher weights after delivery which is one factor that attributes to 
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the growing obesity epidemic (2, 6).  In the USA, approximately 64% of reproductive 
aged women are overweight and 35% are obese which is translated to more than one in 
five pregnant women being obese (7, 8).  Pregnant women accumulate fat as a result of 
enhanced lipogenesis and increased adipose tissue lipoprotein lipase activity.  From mid- 
to late gestation, maternal lipid metabolism switches from an anabolic to a catabolic state 
concomitant with increasing maternal insulin resistance (9).  This increase in insulin 
resistance results in excess weight gain during pregnancy which has detrimental effects 
on offspring (10).  The fetus is not able to regulate their own food intake or growth, so 
they are under the control of their mothers’ nutrient availability.  Figure 1.1 depicts how 
obesity combined with pregnancy leads to an increase in maternal circulating lipids that 
increases the lifetime risk of obesity in offspring as well as metabolic syndrome during 
childhood and adolescence (11, 12).   
 
Figure 1.1. The Effect of Maternal Lipids on Fetal Development and its Consequences in 
Adulthood.  Maternal obesity results in increased inflammation, insulin resistance, lipolysis and 
hepatic very-low-density lipoprotein (VLDL) accumulation in the adipose tissue. These changes 
in adipose tissue phenotype lead to an increase in lipid exposure by a developing fetus, impacting 
organ development and resulting in an increase in the risk for metabolic disease in childhood.  
Monocyte chemotractant protein-1 (MCP-1); chylomicron (CM); triglycerides (TG); lipoprotein 
lipase (LPL); free fatty acid (FFA); nonalcoholic liver disease (NAFLD) (9). 
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The nutritional and hormonal environment encountered by the fetus is a strong 
determinant of not only fetal growth, but also cardiovascular disease risk in later life (13).  
Changes in maternal diet throughout pregnancy modify the mother’s endocrine status 
which can have pronounced effects on the growth and development of their conceptus 
(14).   
Metabolic Stress in Obese Individuals 
Potentially important insights into the mechanisms controlling intrauterine growth 
are provided by recent studies which demonstrate that white adipose tissue is a highly 
active endocrine organ.  Immature adipose tissue first appears in the fetus between 14 and 
16 weeks of gestation in the human and once adulthood is reached, adipose cell numbers 
remain relatively constant (11).  Mature adipose tissue consists of adipocytes, 
macrophages, and stroma-vascular cells which are composed of vascular endothelial 
cells, fibroblasts, and cells of the hematopoietic lineage (11, 15).  Adipose tissue is 
known to secrete a range of hormones that are important in modulating metabolism, 
energy homeostasis and growth, collectively called adipocytokines (16).  These 
adipocytokines can either produce proinflammatory cytokines or metabolic regulators 
that often act as negative regulatory signals that temper the action of hormones and 
growth factors (17).  In obesity, the expansion of adipose tissue mass (not cell number) is 
associated with increased inflammation of adipose tissue (11) which results in an 
imbalance in adipocytokine levels that in the pregnant female can impact the 
development of the growing fetus.   
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IGF-Family:   
The insulin-like growth factor (IGF) system is comprised of IGF-1, IGF-2, the 
two cell surface receptors, IGF-1R and IGF-2R, as well as six binding proteins, IGFBP 1-
6 and proteases which degrade these binding proteins (18).  Overall, the IGF system, in 
combination with growth hormone (GH), accounts for 83% of postnatal body growth 
(19).  The primary mechanism of GH/IGF axis function involves GH-dependent 
stimulation of IGF-1 which regulates both metabolism and growth (20).  IGF-1 is 
predominately produced in the liver in the presence of sufficient nutrient intake and 
elevated hepatic portal insulin levels, but is also synthesized in many other tissues and 
cell types (21, 22).  Interestingly, adipose tissue is a major source of circulating IGF-1 as 
well as IGF-1 being a critical mediator of preadipocyte proliferation, differentiation, and 
survival (22).  IGF-1 concentrations are inversely related to life span, increased cell 
proliferation, and increased IGF-1 levels have been positively correlated with tumor 
progression (17).  Along with GH and the IGF family, insulin is also a central hormone in 
regulating metabolism, capable of stimulating glucose uptake, glycogen synthesis, 
lipogenesis, and prevention of proteolysis (23).  IGF-1 and insulin are known to act in a 
synergistic manner in order to induce adipocyte differentiation.   
The structure of IGF-2 is similar, but not identical to IGF-1 (24).  IGF-2 is known 
to regulate fetal growth and, in an in vitro model of rat adipocyte progenitor cells, 
stimulate adipocyte differentiation (22, 25).  The phenotype of mice lacking IGF-2  
exhibit decreased birth weight compared to control animals, but growth is unaffected 
after birth suggesting that IGF-2 is only essential for prenatal growth (26).  In contrast to 
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IGF-1 which is GH dependent, IGF-2 is, for the most part, GH independent and is 
expressed in most tissues during fetal development, predominantly by cells of 
mesenchymal origin (27, 28).  The activities of IGF-1 and IGF-2 are modulated by three 
distinct mechanisms with the first being the control of ligand expression.  Secretion of 
IGF-1 is sensitive to nutritional and endocrine control and thus is positively related to 
growth rate (17).  Secondly, high affinity binding proteins  are responsible for 
maintaining a large circulating pool of IGF-1 and IGF-2 (29).  Specifically, IGFBP6 
binds to IGF-2 with higher affinity than IGF-1 while other IGFBPs bind to both IGF-1 
and IGF-2 with similar affinities (30).   Finally, tissue specific expression of IGF and 
insulin receptors is an important mechanism that confers specificity of IGF actions.  
IGF-1R, IGF-2R, and insulin receptor are ligand-activated transmembrane 
tyrosine kinases with IGF-1R being widely expressed in many cell types in both fetal and 
postnatal tissues (31).  As depicted in Figure 1.2, the IGF-1R and insulin receptors are 
heterotetramer glycoproteins consisting of two alpha and two beta subunits which recruit 
insulin receptor substrate 1 (IRS-1) to induce phosphorylation and initiate a cascade of 
signal transduction reactions (32).  Insulin receptor shares a high degree of homology 
with IGF-1R, so much so that hybrid receptors naturally occur with full ligand-activated 
signal transduction capacity (17, 28).  The insulin receptor, is comprised of two isoforms 
(A and B) which differ by only 12 amino acids (22).  These receptors are able to bind 
IGFs with a low affinity (28).  Certain cell types are found to contain different receptors.   
For example, preadipocytes express IGF-1R and insulin receptor isoform A, whereas 
mature adipocytes express predominantly insulin receptor isoform A and B (33).  The 
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IGF-1R is known to bind IGF-1 with high affinity and initiates a physiological response.  
It is also able to bind IGF-2, but with a lower affinity, and is responsible for the 
mitogenic effects of IGF-2 during fetal development (34, 35).  The IGF-1R has 
traditionally been viewed in the context of its impact on somatic growth, in particular the 
synergistic relationship with GH that is essential for normal postnatal growth (36).  IGF 
resistance due to receptor desensitization plays a role in growth retardation and metabolic  
 
Figure 1.2. Insulin and IGF Signaling Pathways.  Both Insulin and IGFs share similar signal 
transduction pathways and are able to bind the different receptors with varying affinities.  Ligand 
binding results in MAPK and PI3K signaling pathway activation resulting in transcription, 
proliferation and gene expression (37). 
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disorders which can be caused by a variety of factors including but not limited to 
diabetes, obesity and IGF-1R mutations (17).  The final receptor, IGF-2R, acts as a decoy 
receptor due to it not regulating any significant signaling cascades.  However, IGF-2R 
has been implicated in the regulation of intracellular trafficking of mannose-6-phosphate 
proteins such as lysosomal enzymes (38).  IGF-2 competes for binding with IGF-1R but 
has preferential affinity for IGF-2R over IGF-1 and does not bind insulin receptor (35, 
39).   
 Ligand binding to IGF-1R and insulin receptor results in the phosphorylation of 
the beta subunits and stimulates tyrosine kinase activity.  This phosphorylation results in 
the binding of IRS proteins to the receptors (28).  There are two major pathways that 
have been identified as playing an important role in IGFs cellular proliferation and the 
inhibition of apoptosis (35).  The mitogen-activated protein kinase (MAPK) and the 
phosphoinositide-3 kinase (PI3K) pathways both demonstrate a role in mediating the 
anti-apoptotic and cell proliferative responses of the IGFs (40-42).  IGF-1 is implicated in 
the regulation of adipocyte differentiation and cell cycle by activation of the PI3K 
pathway (22).  Various downstream components of the PI3K pathway are associated with 
enhancing specific cellular events, including metabolism, transcription, hypertrophy and 
differentiation (17).  IGFs also stimulate MAPK which is mediated through Src family of 
nonreceptor tyrosine kinases (43).  On the other hand, pro-inflammatory cytokines have 
been found to exhibit properties that induce a state of IGF-1 resistance (17, 44). 
Both IGFs and insulin are key molecules in mediating the metabolic-related 
function of adipocytes.  IGF-1, which mediates the clonal expansion of preadipocyte cells 
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prior to differentiation, is equipotent with insulin in promoting glucose uptake and 
inhibiting lipolysis in mature adipocytes (23).  Villafuerte et al. (45) looked at adipocyte 
depot-specific expression patterns of IGF-1 (and leptin).  They found that IGF-1 mRNAs 
correlate with adipocyte volume, such that there is increased expression of IGF-1 in 
retroperitoneal compared to subcutaneous fat where retroperitoneal fat has a much greater 
adipocyte volume compared to subcutaneous fat.  They also determined that both leptin 
and IGF-1 function at the autocrine level which could modulate region-specific patterns 
of adipose tissue growth.  Similarly, knowing that individuals with low birth weight have 
an increased risk for metabolic syndrome later in life, a study compared the expression of 
insulin/IGF-signaling molecules in adipose tissue of low-birth-weight and normal-birth-
weight young males.  They found a lower expression of genes for PI3K p85 and p110 
subunits as well as decreased IRS-1 in the adipose tissue of low-birth-weight compared to 
normal-birth weight males (46).  Likewise, in another study, IGF-1R, insulin receptor, 
and AKT are decreased in subcutaneous adipocytes from small for gestational age 
compared to appropriate for gestational age children (47).  These studies show that IGFs 
do indeed play a role in the generation of adipose depots in offspring.  Studies have also 
demonstrated that the IGF system may influence other adipokines such as leptin (48). 
Leptin: 
Leptin (meaning thin in Greek) is a 16-kDa protein containing 167 amino acids 
that was discovered in 1994 by Jeffrey Friedman’s group when a mutation in the obese 
(ob) gene resulted in profound obesity and type II diabetes (49-51).  They characterized 
leptin as an adipocyte-derived hormone which is structurally similar to pro-inflammatory 
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cytokines.  Initially leptin was found to diminish adiposity by reducing food intake while 
improving insulin sensitivity, at least in part by depleting triglyceride stores in peripheral 
tissues (52, 53).  Normally, in peripheral tissues, leptin induces fatty acid oxidation (54) 
and glucose uptake (55, 56) as well as stimulates lipolysis by promoting insulin 
insensitivity in adipose tissue, but not in muscle or liver tissue (57).   
Leptin is a molecule intimately linked with fat and feeding behavior, but it also 
has important reproductive functions, including fetal growth and developmental 
processes such as brain development, 
angiogenesis, hematopoiesis, and 
immune cell function (15, 58).  Mice 
treated with high amounts of leptin 
show accelerated maturation of the 
female reproductive tract which leads 
to an earlier onset of the oestrous 
cycle and reproductive capacity (59).  
Leptin has also been found to be 
synthesized in the placenta of many 
mammalian species even though its 
exact function there is unknown (15). 
 
Figure 1.3. Leptin Signal Transduction Pathway. Leptin binds to its receptor where it activates 
JAK2 which then phosphorylates STAT3.  STAT3 then results in gene transcription to induce 
POMC/CART and inhibit NPY/AGRP (60). 
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Leptin functions through binding its receptors which belong to the cytokine 
receptor superfamily.  The leptin receptor, in turn, activates the Janus Kinase/Signal 
Transducer and Activator of Transcription (JAK/STAT) signaling pathway (Figure 1.3).  
There are five alternatively spliced forms of the leptin receptor which all bind leptin with 
nanomolar affinity (61).  Mutations in the receptor cause an obese phenotype identical to 
leptin deficiency (62).  The activation of the leptin receptor homodimer depends on 
phosphorylation of the kinase Jak2 after ligand binding (63).  Phosphorylation of Jak2 
results in activation of Stat3 as well as leads to tyrosine phosphorylation of SHP-2, a 
phosphotyrosine phosphatase, which decreases both the state of Jak2 phosphorylation and 
transcription of a leptin-inducible reporter gene (49, 64, 65).  Even though many of 
leptin’s effects are mediated through the JAK/STAT pathway, it is also found to 
selectively stimulate phosphorylation and activation of the α2 catalytic subunit of the 5' 
adenosine monophosphate-activated protein kinase (AMPK) pathway in skeletal muscle.  
The activation of AMPK results in the suppression of acetyl CoA carboxylase activity, 
thereby stimulating fatty acid oxidation in muscle (66).  
Leptin’s primary site of action is the brain, where it promotes decreased food 
intake and increased energy expenditure (67).  Specifically, leptin acts at the level of the 
arcuate nucleus which contains orexigenic neuropeptide Y (NPY)/agouti related protein 
(AGRP) and anorexigenic cocaine- and amphetamine-regulated transcript 
(CART)/proopiomelanocortin (POMC) neurons.  Leptin modulates energy homeostasis 
in the melanocortin axis by positively regulating CART/POMC neurons and negatively 
regulating NPY/AGRP neurons (68).  Specifically, POMC neurons have been proposed 
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as the primary cell type for mediating leptin’s anorexigenic effect (68, 69).  POMC is the 
precursor of melanocortin-stimulating hormone which when it acts on its receptor, 
melanocortin-4 receptor, in response to an increased plasma leptin concentration, it 
results in decreased food intake and increased energy expenditure (49).  Corticotrophin-
releasing hormone (CRH) also mediates some of leptin's effects, as pretreatment with an 
anti-CRH antibody blunts the anorexigenic effects of leptin.  Other studies have indicated 
NPY as an important component of the biological response to low levels of leptin and 
possibly starvation (49). 
There are three general ways in which alterations in the leptin signaling pathway 
can result in obesity which are depicted in Figure 1.4.  First, a failure to produce leptin 
can occur.  This would result in unchecked expansion of fat cell mass and consequently 
obesity results.  Second, a regulatory defect can result in decreased leptin production for a 
given fat mass.  This leads to a lower plasma leptin concentration secreted then what is 
expected and results in moderate obesity.  Finally, obesity can result from receptor 
insensitivity to leptin.  An increase in circulating leptin would result from this 
insensitivity and cause increased food intake (49).  The complete loss of leptin or leptin 
receptor is the most severe reported monogenic cause of obesity in mice and humans; 
however, it is extremely rare (70).  In fact, most obese animals have higher leptin levels 
than controls indicating that these forms of obesity are associated with some form of 
leptin resistance (71, 72). 
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Figure 1.4.  Obesity can Result from Three Different Alterations in Leptin Signaling.  
Obesity is generated in three ways in regard to the leptin regulatory loop. a) Failure to produce 
leptin leads to a drastic increase in fat mass, b) inappropriately low leptin secretion for a given fat 
mass leads to fat expanding until ‘normal’ levels of leptin are reached, and c) insensitivity to 
leptin resulting in high leptin levels (49). 
 
TNF-α: 
Tumor necrosis factor alpha (TNF-α) is synthesized as a 26 kDa, 233 amino acid 
transmembrane protein that after cleavage is released into circulation as a 17 kDa, 157 
amino acid soluble TNF-α molecule (73, 74).  TNF-α is predominately produced by 
macrophages (75, 76), but is also produced by a broad range of other cell types including 
endothelial cells, cardiac myocytes, fibroblasts, neurons and adipose tissue.  The 
stimulation of Toll-like receptors and activation of cytokines and lipid mediators lead to 
the increased infiltration of adipose tissue with macrophages which increases TNF-α 
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production.  However, no matter the tissue, TNF-α is a rapidly up regulated cytokine 
whose transcription is initiated within minutes and protein production within a few hours.  
Alterations in this complex regulatory system including over and under expression of 
TNF-α has significant pathological consequences (77).  In adipose tissue, TNF-α inhibits 
lipoprotein lipase, stimulate hormone-sensitive lipase and induce uncoupling protein 
expression.  Also, TNF-α functions to down regulate insulin-stimulated glucose uptake 
(78).  All of these effects reduce lipid accumulation within adipose tissue.  TNF-α has 
also been found to be produced by the placenta during pregnancy where it is able to not 
only induce its own synthesis but also the synthesis of its receptors (78, 79).   
Membrane-bound as well as soluble TNF-α interact with TNF receptors (TNF-R) 
1 and 2 (80).  It is through these receptors that TNF-α can activate cell survival, cell 
proliferation, and apoptotic pathways (Figure 1.5).  These differing effects of TNF-α are 
dependent on the signaling pathways activated.  For example, TNF-α induces apoptosis 
through activation of FADD which binds to caspase-8.  Conversely, TNF-α promotes 
inflammation and survival through TRAF2 via c-Jun NH2-terminal kinase (JNK)-
dependent kinase cascade, MAPK and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathways (81).  While the separate pathways are well defined, 
the balance between cell survival and death remains unclear.  TNF-α has also been found 
to impact other signaling pathways by down regulating insulin-stimulated glucose uptake 
via effects on glucose transporter 4, insulin receptor autophosphorylation and IRS-1 (78). 
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Figure 1.5. TNF-α Signal Transduction Pathway. TNF-α binds to either TNF-R1 or TNF-R2 
which activate signaling pathways to induce apoptosis, cell survival or inflammation (81). 
 
Interestingly, TNF-α was the first discovered adipose-derived factor that indicated 
a link between obesity, inflammation and diabetes.  Upon development of obesity, 
macrophages migrate into the adipose tissue and appear to be the predominant source of 
adipose-derived TNF-α (82).  Studies using genetic models of TNF-α deficiency 
confirmed a causal role for this inflammatory cytokine in the development of obesity-
induced insulin resistance (76).  Furthermore, insulin has been reported to stimulate 
macrophages in adipose tissue to produce more TNF-α (11, 82).  Interestingly, TNF-α is 
involved in ovarian and uterine cyclicity as well as in the establishment of the dialogue 
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between the implanting embryo and the receptive uterus (83).  Likewise, elevated 
circulating TNF-α increases placental produced maternal peripheral blood mononuclear 
cells (84).  Altogether, these data have established the now well accepted paradigm that 
obesity is a chronic condition of low-grade inflammation and activated adipose tissue 
macrophages resulting in increased TNF-α production (4).   
The increase in the production of adipocytokines including IGFs, leptin, and 
TNF-α upon increased maternal adipose tissue mass may directly impact the development 
of the growing fetus.  The placenta, which plays an important role in the transfer of 
nutrients from the mother to the fetus, can also be impacted by these adipocytokines.  
Thus, an indirect effect of increased maternal adipocytokines may be to alter nutrient 
transfer resulting in abnormalities in the development of multiple fetal organ systems.   
Effect of Maternal Obesity on Fetal Growth 
There is a developmental overnutrition hypothesis which proposes that increased 
fuel supply to the fetus due to maternal obesity or overnutrition leads to permanent 
changes in offspring metabolism, behavior, and appetite regulation (8, 85, 86).  A study 
by Parsons et al. (87) in humans found that heavier mothers give birth to heavier babies 
which go on to have a high BMI in adult life as well as are at an increased risk for 
metabolic syndrome, asthma and developmental abnormalities (88-90).  Even though 
human studies have found a prevalence for large-for-gestational-age (LGA) fetuses, 
maternal obesity has also been associated with intrauterine growth restriction (IUGR) in 
humans as well as in rodents and livestock species (91-93).  Interestingly, both LGA and 
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IUGR result in offspring exhibiting similar developmental abnormalities (94-97).  This 
may be due to catch-up growth in IUGR infants which could put them at a higher risk for 
metabolic syndrome in adulthood (98) as well as the postnatal accelerated growth 
adversely affecting glucose tolerance in rats (99). 
 Based on these data, it is clear that maternal overfeeding and adiposity prior to 
pregnancy has a significant impact on fetal, neonate, and adult growth.  Furthermore, this 
effect on growth has been correlated to alterations in fetal organ development (100).  
Animal models (mainly rodents and sheep) have proven to be invaluable tools to define 
the mechanistic links between maternal diet and body composition as well as the 
offspring phenotype of metabolic syndrome (101-103).  For example, prenatal 
overfeeding in the rat, mouse, and sheep leads to altered appetite regulation in the 
postnatal offspring (97, 104, 105) which may be due to programming changes at appetite 
centers in the hypothalamus (86, 92, 106).  This altered appetite regulation is tied to the 
increased fat deposition resulting in postnatal weight gain and eventually offspring 
obesity.  Prior to birth, embryos from mice fed a high fat diet display significant growth 
retardation, with live pups being significantly smaller at birth compared to control fetuses 
(93).   
The development of the cardiovascular system, liver, and pancreas may be 
particularly sensitive to pre-conception and/or early gestational changes in maternal body 
composition and metabolism beyond what is compensated for by fetal visceral fat 
deposition (100).  Excess energy is normally stored as visceral fat, but if stores are 
surpassed, circulating lipid levels are increased.  Indeed, offspring from obese dams are 
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found to display not only higher percentage of body fat (97, 107), but also increases in 
triglyceride levels (108) which together can predispose the animal to postnatal 
development of metabolic disease (e.g. fatty liver disease) (100, 109).   
Along with the impact of increased adiposity on fetal growth and metabolic 
disturbance, there is evidence that maternal obesity in rodents and ewes can predispose 
offspring to alterations in organ development.  For example, pancreas weight is increased 
and displays enhanced early β–cell maturation in offspring from obese dams (100, 102, 
107).  A similar increase is also seen in regards to liver weights which have been shown 
to lead to the development of nonalcoholic fatty liver disease (100, 108, 110).  Animal 
studies also suggest that the vasculature of the offspring is significantly affected by 
maternal high-fat diet during pregnancy.  A study in non-human primates showed that 
offspring of mothers fed a high-fat diet had a threefold reduction of dilation capacity in 
the abdominal aorta, increased intimal wall thickness and an increase in the expression of 
vascular inflammation markers, suggesting a negative effect of maternal high-fat diet on 
offspring endothelial function (111).  These data represent a potential mechanistic link 
between maternal obesity and the development of high blood pressure (97, 112-114) seen 
in animal models.  However, despite this animal evidence, there has been no data in 
humans that explains the association between maternal obesity and blood pressure (85).  
Interestingly, there are also sexually dimorphic differences in the impact of maternal 
obesity on organ function, particularly in relation to glucose homeostasis and liver 
weights.  A study by Samuelsson et al. (97) found that liver weights are increased in male 
offspring but not in female offspring.   
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Maternal Obesity Alters Muscle Development 
The impact of maternal obesity on skeletal muscle development is of particular 
importance.  Skeletal muscle is a major metabolic organ and alterations in muscle 
development could result in long-lasting effects on the metabolic health of offspring.  
Skeletal muscle development is known to have a lower priority in nutrient partitioning 
than the development of the neural system, internal organs, and bone, making it 
susceptible to nutrient fluctuation (115).  Due to this fact, studies have been conducted 
that look at the effects of an altered maternal diet on embryonic muscle development.  
One study carried out by Larciprete et al. (116) used ultrasonic measurements of IUGR 
fetuses to show a reduction in muscle mass in these IUGR fetuses.  Likewise, Zhu et al. 
(117) indicate that maternal nutrient availability is associated with the number of 
secondary fibers present in prenatal muscles.  During early and mid-gestation in the ewe 
nutrients have been shown to reduce skeletal muscle fiber density suggesting 
abnormalities in myotube formation (118, 119).  The incorporation of additional 
myoblasts into the myofiber during fetal development continues via fiber hypertrophy 
and requires additional myoblast incorporation to increase genomic DNA content (120, 
121).  However, in fetal sheep with placental insufficiency caused by alterations in 
maternal nutrients, skeletal muscle fibers contain fewer myonuclei than fibers from 
control fetuses, resulting in less DNA, RNA and protein per fiber (122).  Also, Huang et 
al. showed that maternal obesity enhances collagen content and crosslinking in fetal 
skeletal muscle, which might be due to reduced collagen remodeling, and leads to fibrosis 
which impairs muscle function and is a hallmark of muscle aging (123).  These 
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alterations that are occurring in muscle may be impacting the myogenic program and 
altering the stages of skeletal muscle development (Figure 1.6).  The pre-adipocyte 
marker, peroxisome proliferator-activated receptor γ (PPARγ), has also been found to be 
expressed in higher concentrations in skeletal muscle of offspring from obese dams 
indicating increased intramuscular adiposity in offspring from over nourished mothers 
(119, 124).  In addition to abnormalities in muscle mass, the metabolic function of 
muscle is also impaired in fetuses of obese dams with obesity during pregnancy causing 
defects in insulin-signal transduction (125). 
 
 
Figure 1.6.  Stages of Bovine Fetal Skeletal Muscle Development.  The progression through 
the various bovine fetal skeletal muscle developmental stages during gestation may be impacted 
by nutrient restriction or excess. The stage in which the nutrient deficiency or excess occurs will 
determine what organs are impacted based on their developmental program.  Adapted from (140). 
 
Maternal obesity dependent reductions in myogenesis and increased intramuscular 
fat in the late gestation fetal sheep has been associated with increased expression of 
inflammatory markers and altered AMP-activated protein kinase signaling (119, 126, 
127).  Skeletal muscle, which is the largest tissue in the body, synthesizes and responds to 
many inflammatory mediators.  For example, elevated proinflammatory cytokines 
including TNF-α are implicated in muscle wasting (128, 129).  This muscle wasting may 
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be a result of inflammatory cytokines suppressing IGF-1 signaling in myofibers and 
myoblasts.  Indeed, TNF-α has been shown to decrease IGF-1 mRNA by 80% (17, 130).  
Along with the impact of proinflammatory cytokines, high maternal glucocorticoid levels 
have been shown to impair fetal skeletal muscle growth (131).  In mature muscle, 
glucocorticoid exposure decreases muscle protein synthesis and promotes protein 
degradation (132).  Thus, increased glucocorticoid levels during gestation may negatively 
impact muscle development by disrupting the differentiation process resulting in 
decreased muscle mass.  During normal development, skeletal muscle development is 
induced by reduced O2 availability, or hypoxemia.  Embryonic somites have been shown 
to exhibit increased expression of hypoxic markers prior to the formation of local blood 
vessels and embryonic muscle (133) with hypoxemia increasing the undifferentiated state 
of muscle stem cells.  However, a chronic hypoxic environment diminishes the 
differentiation of muscle stem cells which promotes self-renewal divisions without 
affecting the overall proliferation of primary myoblasts (134). 
Previous studies have focused on the impact of maternal obesity on skeletal 
muscle development during late gestation (secondary myogenesis) and the phenotype of 
skeletal muscle in the adult offspring.  However, there is a gap in understanding how 
maternal obesity affects primary myogenesis and the consequences of potential 
alterations during primary myogenesis on the later stages of muscle development.  In 
order to understand the alterations that are occurring in muscle development due to 
maternal obesity, it is imperative to understand how skeletal muscle normally develops.  
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Normal Skeletal Muscle Development 
The fetal period is crucial for skeletal muscle development due to no net increase 
in the number of muscle fibers after birth (117, 122, 135).  Adult skeletal muscle consists 
of about 40-50% of the total body mass (136) and is a key metabolic organ which is 
responsible for the oxidation of glucose and fatty acids (126).  The myogenic program is 
a highly conserved process in all species (137).  However, the formation of secondary 
myofibers and adipogenesis begins around mid-gestation in humans, sheep and cattle 
(138), while rodents are born highly immature with secondary myogenesis occurring late 
in gestation and continuing throughout the neonatal period (126, 139).  Thus, even though 
there is a difference in the timing of myogenesis, the process and its regulation is still 
very similar. 
The Somite Region Harbors Muscle Progenitor Cells: 
All skeletal muscles in the body arise from muscle founder stem cells located in 
the somites.  Somites are transitory structures that form in pairs, on either side of the 
neural tube, as epithelial spheres from the presomitic paraxial mesoderm (Figure 1.7) 
(141, 142).  Somites begin forming at the anterior (head) end of the embryo and are 
added posteriorly (tail) as the embryo extends. This means that the anterior somites are 
more developed than the posterior somites and result in a range of somite stages within a 
single embryo (137).  Since an anterior/posterior developmental gradient occurs in 
somitogenesis, there is also a difference in limb formation with the forelimbs forming 
before the hindlimbs (139).  Once somitogenesis is complete there are a total of 60 pairs 
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Figure 1.7.  Spatial Representation of Somite Development.  Segmentation of the presomitic 
paraxial mesoderm into ball-like structures, known as somites, occurs along the dorsal–ventral 
axis and in an anterior to posterior direction. In response to signals from the notochord and the 
neural tube, the somites differentiate and subdivide to give rise to the dermomyotome and the 
sclerotome which result in the development of many different tissues and organs throughout the 
body (143). 
 
of somites in the developing mouse embryo (139).  The somites harbor progenitor cells 
that give rise to not only skeletal muscle, but also cartilage, endothelial cells, tendons, 
connective tissue and the dermis of the back (144). 
As the cells of the somite proliferate, they divide into multiple distinct regions 
(Figure 1.8); the sclerotome which gives rise to vertebral and rib cartilage, dermal 
lineages, and blood vessel lineages and the dermomyotome (DM) which harbors skeletal 
muscle progenitor cells (MPC) of the trunk, limbs and some head muscles as well as 
dermal progenitors (139, 141, 145).  The DM has a region that lies directly below it 
called the myotome.  Further, both the DM and the myotome are divided into two 
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regions, epaxial and hypaxial.  The epaxial region gives rise to the deep muscles of the 
back, while the hypaxial region produces the rest of the body and limb musculature (137, 
142).  Even more specifically, the DM has two regions on the ends, the ventral lateral lip 
(VLL) and the dorsal medial lip (DML).  The VLL progenitors delaminate from limb 
level somites and migrate to limb buds to form limb muscles (145).  Medial DM cells as 
well as the cells at the DML produce the epaxial muscle progenitors that migrate 
underneath the DM.  These cells then differentiate into mononucleated myocytes to form 
the myotome which is the region where the first skeletal muscles form (133, 141, 146, 
147). 
 
Figure 1.8.  Somite Origin of Myogenic Progenitor Cells. Myogenic progenitors originate in 
the dorsal-medial lip (DML) and ventral-lateral lip (VLL) of the dermomyotome. Cells of the 
dorsal medial lip (DML) migrate under the dermomyotome to form the epaxial myotome. A 
similar event occurs at the ventral lateral lip (VLL), which results in the formation of the hypaxial 
myotome. Cells of the VLL also undergo an epithelial to mesenchymal transition, delaminate and 
migrate to regions of limbs for muscle development (145). 
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As somites develop, the complex muscle differentiation process is occurring in 
tandem.  Myogenesis has multiple waves in the developing embryo that build the 
framework for adult musculature.  As shown in Figure 1.9, the mouse has its first 
embryonic wave of muscle development around embryonic day (E) 8.5 which continues 
until around E 14.5.  During this wave, quiescent myogenic stem cells (MSC) are 
activated and proliferate making them muscle progenitor cells (MPC) (Figure 1.10).  
During this time MPC further differentiate into myoblasts which are able to begin to 
differentiate and fuse to form primary fibers or myotubes.  Those primary fibers then act 
as a scaffold for the formation of fetal (secondary) fibers which occurs in the fetal wave 
of muscle development (E 14.5 - E 16.5).  Around E 16.5, the late fetal wave begins 
which is the final wave where secondary fibers fill in the spaces not already occupied by 
existing fibers and complete myogenesis (148).   
Figure 1.9.  Waves of Developmental Myogenesis in the Mouse.  The early embryonic wave 
begins around embryonic day (E) 8.5 and results in the formation of primary fibers.  The fetal 
wave, between E 14.5 and E 16.5, consists of the scaffolding of secondary fibers.  Around E 16.5, 
proliferating myotubes form muscle fibers completing myogenesis.  Adapted from (141, 149, 
150). 
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Myogenic Regulatory Factors: 
The process of differentiation from MSC to myotubes is dependent on the temporal 
expression of several transcription factors which belong to the basic-Helix-Loop-Helix 
(bHLH) family (Figure 1.10).  These myogenic regulatory factors (MRFs) include 
myogenic determination factor 1 (MyoD), myogenic factor 5 (Myf5), myogenic regulator 
factor 4 (Mrf4, also known as myogenic factor 6-Myf6 when first discovered) and 
myogenin (Myog, also known as myogenic factor 4-Myf4 when first discovered) (151, 
152).  The expression of two paired box (Pax) transcription factors, Pax3 and Pax7, is the 
first step in differentiation of DM progenitor cells to skeletal muscle (141).  Pax3 and 
Pax7 are also members of the bHLH family of transcription factors and are expressed in 
the central nervous system, neural crest cells and somites.  Their expression is necessary 
for the emergence and survival of MPC and the regulation MRFs (141, 149).  In a 
Figure 1.10.  Gene Expression Profiles during Myogenesis.  Myogenic stem cells (MSC), 
myogenic progenitor cells (MPC), myoblasts, and the multinucleated myotube express different 
genes during myogenesis (148). 
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coordinated fashion, MRFs form heterodimeric DNA-binding complexes with other 
bHLH transcription factors such as the E2 gene family (E47 and E12) and bind a 
canonical DNA sequence (CANNTG, also referred to as an E box) to regulate the 
expression of an array of genes that regulate the assembly of skeletal muscle (145, 153, 
154).   
The switch from MSC to MPC marks the start of differentiation (137) with the 
temporal activation of MRFs regulating the myogenic program (outlined in Figure 1.10).  
Specifically, in the developing embryo Pax7 plays a large part in the activation of MSCs 
which begins the differentiation process into mature muscle (155).  The activation of 
Pax7 results in the expression of Myf5 which is the earliest marker of MPC and is closely 
followed by MyoD expression.  Myf5, MyoD and Mrf4 are all co-expressed in MPC as 
well as myoblasts and play a role in the establishment and maintenance of muscle 
progenitor lineages by directing the developmental program during embryogenesis (156-
159).  Due to the Myf5 and MyoD transcripts being relatively unstable, their continued 
expression requires constant signals from the neural tube and notochord in order for these 
cells to later initiate myotome differentiation (160).  Further differentiation is marked by 
the onset of Myog expression and the formation of myoblasts (Figure 1.10) (161, 162).  
Under the proper signals, levels of Myog will increase, followed by up-regulation of Des 
(Desmin) (163, 164).  DES, an intermediate filament protein, is expressed in 
differentiated myotubes that, along with MYOG expression, is critical for muscle 
formation during embryogenesis, however is not needed for proper muscle differentiation 
in adulthood (141, 165).  In adult myofibers, the expression profile switches to Mrf4, 
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whereas MyoD, Myf5 and Myog expression is relatively lower, making Mrf4 a 
predominant factor in adult muscle (166). 
Satellite Cells in Adult Muscle: 
Towards the end of fetal muscle development (around E16.5) (10), MSC begin to 
be enveloped under a basal lamina that forms around the muscle fibers (133).  In 1961, 
Alexander Mauro discovered and termed these cells satellite cells (167).  Satellite cells 
arise from a novel population of MSC that express both Pax3 and Pax7 (133, 168).  
However, while Pax3 is not solely required for satellite cell emergence or maintenance, 
Pax7 is required otherwise they will fail to repopulate the stem cell niche and eventually 
die (133, 168, 169).  In newborn animals, the proportion of satellite cells in muscle is 
higher.  It is during this time that they participate in proliferation and adding nuclei to the 
growing muscles.  Once growth is achieved, satellite cells become quiescent and 
represent a very small proportion of nuclei in adult muscles (170).  For example, the 
number of satellite cells in muscle declines after birth from 30% of myonuclei in the 
juvenile phase (0 - 3 weeks) to 4% in the adult phase (3 weeks to ~18 months), followed 
by a small decrease to 2% in aged mice (18 months to end of life) (171, 172). 
Adequate satellite cell availability is needed for proper muscle maintenance and 
repair after injury in the adult animal (Figure 1.11).  Muscle satellite cells are normally 
quiescent, expressing both Pax7 and Myf5, but lacking MyoD expression (173, 174).  
When muscle fiber is damaged, satellite cells become activated.  At this time satellite 
cells can either replicate and differentiate to form new fibers permitting muscle repair or 
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they will become renewed satellite cells allowing for repopulation of the satellite stem 
cell niche (173, 175).  When a satellite cell is activated, they will express the MYOD 
protein which is the hallmark of an activated satellite cell.  The satellite cell then will 
either lose MYOD expression and maintain PAX7 expression as they will leave the cell 
cycle and self-renew (176) or will retain the MYOD expression.  If retained, MYOG 
expression is activated to signal terminal differentiation to a mature myoblast (173).  The 
terminal differentiation results in the fusion of the recently differentiated myoblast to 
form nascent multinucleate myofibers or fuse with myofiber end-fragments to develop a 
new muscle fiber (148).  So, MYF5 and MYOD commit progenitors to a muscle fate 
whereas MYOG is required for terminal differentiation of committed progenitors (141). 
 
Figure 1.11.  Expression Profile of Satellite Cells. The proliferating myoblast population is 
represented by the Pax7+/MyoD+ mononuclear cells. Nuclei that are MyoD+/Myog+ (and no 
longer express Pax7) are found within differentiated mononuclear cells and myotubes, whereas a 
minor population of Pax7+/MyoD+/Myog+ cells represents a transitional stage within recently 
differentiated myoblasts; newly formed myotubes occasionally display Pax7+/ MyoD+/Myog+ 
nuclei as well. Renewed cells Pax7+/MyoD− represent reentry into the satellite cell niche (177). 
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Signals Impacting Muscle Development 
Neural Tube Regulation of Myogenesis: 
Secreted factors from the neural tube, notochord and surface ectoderm regulate 
the myogenic program including regulating the expression of MRFs and Pax transcription 
factors (Figure 1.7).  While the notochord releases signals that are required for the 
activation of MRFs, the signals from the neural tube aid in the maintenance of MRF 
expression during somite maturation prior to the initiation of myotome differentiation 
(178).  Both the neural tube and notochord provide essential signals specific for the 
formation of epaxial muscles, but not for hypaxial or limb muscles (179).  These signals 
from the adjacent notochord, neural tube, and surface ectoderm impinge upon the cells in 
the DM to regulate the emergence of MPC (141, 148).   
Factors secreted by the neural tube including Notch, Wnt, Sonic Hedgehog (Shh), 
and Bone Morphogenetic Proteins (BMPs) function in the activation of MSCs, their 
downstream progeny, and their lineage progression (Figure 1.12) (180).  Notch signaling 
is necessary for the initial phases of myogenesis and MSC maintenance in DM cells 
which is activated by mild hypoxia (134, 181, 182).  The Notch signaling pathway is 
responsible for the reduction in the proliferative capacity of the Pax3 and Pax7 positive 
MSCs (183).  If the Notch signaling pathway is disrupted, the progenitor pool depletion is 
accelerated due to their commitment to myogenesis thereby compromising muscle 
development (141).  A sustained activation of Notch reverses the myogenic program, 
resulting in a downregulation of Myf5 and MyoD expression and a return to a quiescent 
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MSC state (181).  There is some evidence that MSC self-renew through asymmetric cell 
divisions is controlled by not only the Notch but also Wnt signaling pathways (184-186).  
Canonical Wnt signaling, which follows Notch, promotes differentiation of satellite cells 
to become muscle fibers (187).  Specifically, Wnt6, produced by the surface ectoderm, 
activates Pax3 to initiate further differentiation into MPC (188, 189).  Wnt signaling has 
also been shown to regulate the initiation of Sonic hedgehog (Shh) signaling from the 
surface ectoderm and dorsal neural tube during somite formation (190).  Shh is an 
essential and sufficient notochord signal for Myf5 and MyoD activation (190-192).  
Noggin, a secreted BMP antagonist, also regulates Myf5 and MyoD expression by 
inhibiting Bmp4 signaling from the neural tube (193).  Altogether, the activation of Myf5 
and MyoD genes in the 
somite, as well as in 
the limbs, depends on 
signaling from Wnts, 
Bmp4, Noggin, and 
Shh (139, 193, 194).   
 
 
 
Figure 1.12.   Signals from Surrounding Tissues Impact Myogenic Markers. Signals from 
adjacent lineages, notochord, neural tube, and surface ectoderm, impact the expression of genes 
in the dermomyotome, myotome, and sclerotome (148). 
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While the mechanisms are not clear, it is likely that factors expressed due to maternal 
obesity alter these signaling pathways and therefore disrupt myogenesis. 
Neural Crest Cell Regulation of Myogenesis:  
In addition to neural tube signals that impact myogenesis, neural crest cells also 
play a part in the regulation of muscle development. Neural crest cells originate in the 
neural tube and go through a transformation where they delaminate and migrate away 
from the neural tube to diverse regions in the developing embryo (Figure 1.13) (195-
200).  One region they migrate past following somite maturation is the anterior half of the 
sclerotome and along the basement membrane of the DM (201, 202).  It is in this region 
that they play a part in the regulation of myogenesis (200, 201, 203).  In order for neural 
crest migration to occur these cells must undergo an epithelial-mesenchymal transition 
(EMT).  EMT is a mechanism where epithelial cells are converted to a mesenchymal 
phenotype.  In order for this to occur, the expression of Snail, Twist and Zeb2 are needed 
to repress the expression of epithelial polarity/adhesion factors (e.g. E-cadherin) (204).   
Along with neural crest cells providing signals to the surround cells, they are also able to 
differentiate into neurons, cartilage, melanocytes, the dorsal root ganglia and many other 
types of cells (149, 200, 203).  
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Figure 1.13.  Migration Pattern of Neural Crest Cells.  Trunk neural crest cells in the mouse 
migrate from the neural tube (NT) through the dermomyotome (d) and sclerotome (scl) and 
impact myogenic differentiation. Somite (s); and notochord (n) (200). 
 
Functional signaling exists between neural crest cells and MPC in early muscle 
development where they aid in the survival of the MPC and maintain them in an 
undifferentiated state (181, 205).  Neural crest cell migration is limited to a short time 
period during early development, and therefore, neural-crest-mediated regulation of 
muscle growth is limited to the initial phases of myotome formation (181).  Specifically, 
when somites are going through the embryonic wave of myogenic differentiation 
characterized by expression of MYF5, neural crest cells are migrating from the neural 
tube and playing a role in regulating this stage of muscle development (181).  Hence, the 
timing of myotome formation to that of neural crest migration may provide a mechanistic 
link for the concurrence of these two events (181, 199).  Moreover, neural crest cells have 
been found to secrete Neuregulin1 which plays a part in muscle regulation by restraining 
MPC from precocious differentiation (205).  Interestingly, the depletion of migrating 
neural crest cells has been shown to compromise myogenesis by altering the balance 
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between Pax7 positive progenitors and differentiating muscle (181, 205).  Altogether, 
MPC rely on the migration of neural crest cells to trigger the transient activation of Notch 
signaling which guarantees a balanced and progressive differentiation of the MPC pool 
(181).   
Fetal Programming is Impacted by Maternal Environment 
Fetal growth and development are influenced by genetic as well as environmental 
factors (206).  The overall fetal response to its in utero environment is defined as “fetal 
programming” (207).  Fetal programming involves developmental plasticity with 
disturbances during critical periods of fetal development altering the differentiation of 
specific cells, organ systems or homeostatic pathways (208, 209) which persist into adult 
life.  Furthermore, the postnatal environment may either mask or magnify the effects of 
programming on the expression of a phenotype (98).  Two of the major environmental 
factors that have been proposed to influence fetal programming are malnutrition and 
stress.  For example, many have hypothesized that the macro- and micro-nutrient 
components of the diet, together with caloric content, act to set the cellular control of 
energy oxidation and storage (210).  Likewise, maternal overnutrition can stimulate 
programming mechanisms which regulate mitochondrial bioactivity, cellular stress and 
inflammation (210).  Altogether, the nutrient status of the mother during pregnancy is 
responsible for the development of the placenta (211), which is a key organ in respiratory 
gas, nutrient, and waste exchange between the mother and fetus.  If alterations in 
placental development occur, the growth and future health of the fetus may be impacted 
(10).   
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Placenta’s Role in Embryonic Development 
The late, eminent reproductive physiologist Samuel Yen referred to the placenta 
as the ‘third brain’ in pregnancy in recognition of the regulatory nature of placental 
function (15).  The placenta acts as an important source of pregnancy-associated 
hormones and growth factors, and is involved in immune protection of the fetus (212).  
The placenta itself is derived from the trophectoderm with the number of cells that 
differentiate into this lineage determining its developmental potential (213).  Specifically, 
at the time of implantation the trophectoderm cells become trophoblast giant cells (212, 
213).  The cells immediately adjacent to the inner cell mass are then transformed in a 
number of ways to differentiate into the remaining placental structures (Figure 1.14).  
One of these ways is when the trophoblast, with its associated fetal blood vessels, 
undergoes extensive villous branching to create a densely packed structure called the 
labyrinth (212).  While the labyrinth is developing, it is supported structurally by the 
spongiotrophoblast, which form a compact layer of non-syncytial cells between the 
labyrinth and outer giant cells which is in contact with maternal blood (15, 212).  The 
fetal vascular compartment of the placenta arises from the allantoic mesoderm of the 
embryo while the maternal components are derived from the maternal vasculature and 
decidual cells (212).  Maternal nutrients are able to be exchanged when blood enters the 
small spaces of the labyrinth where it flows in a countercurrent manner with fetal blood 
in the trophoblastic villi to maximize nutrient transport (212, 214).   
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Figure 1.14.  Structure of the Mouse Placenta.  The mouse placenta is composed of a labyrinth, 
spongiotrophoblast, trophoblast giant cell layer and maternal decidua.  The labyrinth layer 
consists of fetal capillaries and maternal blood and is the site of nutrient and gas exchange 
between the fetal and maternal blood (213). 
 
During the early phase of fetal development (i.e. the first two-thirds of gestation) 
maximal placental growth, differentiation, and vascularization are occurring (211, 215).  
It is during this time that an adequate establishment of the uteroplacental blood flow is 
needed to allow for exchange of all respiratory gases, nutrients, and waste products 
between the maternal and fetal systems (211, 216-219).  Placental function is a dynamic 
process which is influenced by maternal diet, body composition and lifestyle and has an 
important regulatory role in maternal well-being during pregnancy (11).  If an altered 
nutrition and hormone profile occurs, changes in nutrient transfer and partitioning 
between mother, placenta, and fetus results which modifies placental weights (220).  
Interestingly, placental weight is used to predict growth and long-term health of the fetus 
(221) and under normal conditions, placental and fetal weights are highly correlated (222, 
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223).  Abnormalities in maternal metabolism (e.g. due to obesity) alters the balance 
between placental and fetal weight (224, 225).  In addition, normal processes of placental 
function like oxidative stress and hypoxia can be altered due to maternal obese 
environment.  Together, these alterations can contribute to differences in the normal 
program of fetal development.  These changes then result in altered differentiation of the 
developing fetus due to changes in uteroplacental blood flow, placental metabolism of 
glucocorticoids and the transport of nutrients to the developing fetus.   
Oxidative Stress: 
The syncytiotrophoblast cells come in direct contact with the relatively high 
oxygen concentration in maternal blood, but have reduced levels of antioxidants making 
the placenta highly susceptible to oxidative stress (226).  Sources of oxidative stress 
including nutritional and environmental factors play a major role in the susceptibility of 
programming disease in offspring (227).  Oxidative stress is a result of the generation of 
reactive oxygen species (ROS) in the absence of sufficient antioxidant support (228, 
229).  There are three ROS: superoxide (O•−2), hydrogen peroxide (H2O2) and hydroxyl 
(OH•) (228, 230, 231), all of which are in a more reactive state than molecular oxygen 
and are generated within the cell as by-products of aerobic respiration and metabolism.  
The generation of O•−2 by a single electron donation to O2 is the initial step in the 
formation and propagation of ROS within and out of the cell (Figure 1.15).  The 
formation of O•−2 leads to a cascade of other ROS development.  For example, 
dismutation of O•−2 produces H2O2 which can be reduced to H2O and O2 by various 
antioxidants.  Likewise, in the presence of iron, O•−2 is converted to OH•.  Interestingly, 
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due to the ROS have a very short half-life, the development of oxidative stress in the 
placenta does not directly affect signal transduction and cell survival in the developing 
embryo.  However, placental changes as a result of an adverse maternal environment may 
induce oxidative stress in the embryo (232).  If uncontrolled, ROS can damage different 
biological targets such as lipids, DNA, carbohydrates and proteins and compromise cell 
function (228, 229, 233).   
During a normal pregnancy, there is an important balance between ROS 
production and antioxidant defenses (234).  This balance is altered to favor ROS 
production in pregnancies complicated by obesity resulting in the development of an in 
utero environment of oxidative stress (Figure 1.16) (235).  The production of ROS is 
facilitated by growth factors and cytokines like insulin, transforming growth factor beta 
(TGFβ), or TNF-α which are normally increased due to an obese environment.  Also, 
major sources for intracellular ROS are the mitochondria, which generate O•−2 and H2O2 
as byproducts of cellular energy production (236).  All of these factors increase the 
generation of O•−2 through the activation of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases or via mitochondrial antioxidants (237, 238).  There are a number of 
steps where antioxidants work to control the exposure of cells to O•−2 with the first being 
conversion of O•−2 to H2O2 by superoxide dismutases (SOD) (Figure 1.15).  There are 
three different SODs: SOD1 which contains Cooper and Zinc and is located in the 
cytoplasm, Manganese containing SOD (SOD2) which is located in the mitochondria and 
extracellular SOD3 which contains Copper and Zinc (230).  In addition to SODs, the 
antioxidants glutathione peroxidase 1 and catalase are reducing enzymes which convert 
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H2O2 to O2 and H2O and therefore limit cell exposure to H2O2 (Figure 1.15).  They also 
act on lipid hydroperoxides (233).  All of these antioxidants, along with non-enzymatic 
dietary antioxidants (239), work together to defend the body against oxidative stress 
(Figure 1.16).  
 
 
Figure 1.15.  Oxidative Stress Results from the Production of Reactive Oxygen Species.  
Reactive oxygen species (ROS) are produced from  molecular oxygen (O2) being converted to 
hydroxyl radicals ( OH).  There are multiple key cellular antioxidant enzymatic pathways that try 
to convert ROS back into O2 and water (H2O). Superoxide anion ( O2−); hydrogen peroxide 
(H2O2); copper–zinc containing SOD (Cu,Zn-SOD or SOD1); manganese containing SOD (Mn-
SOD or SOD2); catalase (CAT); glutathione peroxidase (GPX) (230). 
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Figure 1.16.  Prooxidant-Antioxidant Imbalance Results in Oxidative Stress.  A balance is 
needed between the amount of antioxidants and ROS present in order to not create an oxidative 
stress environment.  Reactive oxygen species (ROS); antioxidant (AOX); superoxide dismutase 
(SOD); glutathione peroxidase (GPX); catalase (CAT); total antioxidant status (TAS) (233). 
 
Small changes in ROS associated with maternal obesity modulate the expression 
of genes via activation of multiple signaling pathways  (98).  For example, ROS activate 
members of the JNK and p38 stress kinase family, MAPKs, PI3K, and NF-κB (238).  The 
JNK and p38 stress kinase family mediate inflammatory cytokine- and stress-induced 
apoptosis and stress-responsive gene expression functions through the phosphorylation of 
the Forkhead Box (FOXO) family of transcription factors (240).  ROS are known to 
promote FOXO1 translocation to the nucleus of β–cells by a mechanism that involves 
activation of JNK and the phosphorylation of FOXO (241).  The JNK-induced 
phosphorylation by oxidative stress overrides the effects of FOXO phosphorylation, 
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which then provides a mechanism where oxidative stress results in an increase in insulin 
sensitivity (242).  The activation of FOXO transcription factors due to increased 
oxidative stress can also induce the expression of a wide range of genes that regulate 
cellular responses such as cell cycle arrest, apoptosis.  Interestingly, FOXO transcription 
factors also stimulate the expression of SODs and antioxidants in order to alleviate the 
oxidative stress (237, 243, 244).  ROS are also known to activate MAPKs which are 
protein serine/threonine kinases which play an important role in cell differentiation, 
growth, apoptosis, via the activation of a variety of transcription factors which regulate 
target gene expressions (245).  Finally, PI3K is activated in response to ROS which 
induces cell growth, proliferation, differentiation, motility, and survival while NF-κB 
signaling results in growth control, immune response to infection, and inflammation 
(246).  Altogether, all of these pathways are activated in response to oxidative stress 
which can have a negative impact on placental nutrient regulation impacting embryonic 
development. 
Hypoxia: 
Oxidative stress is also induced by hypoxia (247, 248).  Hypoxia occurs when 
oxygen availability does not match the demand of the surrounding tissue, resulting in 
decreased oxygen tension (249).  For example, if oxygen supply is equal to the oxygen 
demand then a state of normoxia results but, if oxygen supply is not enough to fulfill 
tissue demands then a hypoxic environment results.  Hypoxia was first proposed as a 
possible cause of inflammation in obesity in 2004 (249-251) when hypoxia was found in 
only the adipose tissue of obese mice (251).  The decreased perfusion as well as 
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decreased blood flow per blood vessel occurs in adipose tissue of obese mice (249).  
Systemic hypoxia has also been shown to induce insulin resistance as glucose infusion 
rate was decreased which occurs in obese individuals (251, 252).  Hypoxia has been 
found to stimulate both leptin and vascular endothelial growth factor (VEGF) from 
mature adipocytes in vitro as well as being the primary signal for angiogenesis (249, 253, 
254).  Inflammation in adipose tissue is induced by hypoxia due to the induction of gene 
expression in adipocytes and macrophages (255).   
Low oxygen tension is important in many normal physiological processes in the 
adult animal including postnatal growth, differentiation and migration.  During 
embryonic development, low oxygen tension promotes the establishment and 
differentiation of the vascular and hematopoietic systems (256).  However, reductions in 
oxygen tension, to the level of hypoxia, are known to differentially regulate cell 
differentiation and therefore alter the fetal developmental program (247).  For example, 
hypoxia plays a major part in inhibiting the differentiation of preadipocytes into 
adipocytes and myoblasts into myocytes (257) which leads to decreased fetal growth and 
skeletal anomalies (258).   
Cells respond to hypoxia by coordinating expression of numerous genes to ensure 
adaptation (249).  The primary pathway that responds to tissue hypoxia is the hypoxia 
inducible factor (HIF) signaling cascade.  The HIF signaling cascade is activated in 
response to low oxygen availability and is central in maintaining oxygen homeostasis 
(256, 259).  The HIF signaling cascade is composed of a HIF-1β subunit and one of the 
three HIFα subunits (HIF-1α, HIF-2α or HIF-3α).  It also contains prolyl hydroxylase 
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domain-containing proteins (PHDs) which aid in the regulation of HIF signaling.  There 
are three types of PHDs with each having a distinct tissue distribution, pattern of 
subcellular localization, and substrate specificity (260).  PHD2 is the rate-limiting 
enzyme that sets the low steady-state levels of HIF-1α in normoxia, whereas PHD1 and 
PHD3 contribute to HIF-1α regulation only upon chronic hypoxia (261).   
 
Figure 1.17.  Hypoxia/Normoxia Signaling Cascade. Hypoxia inducible factor (HIF)-1α is 
degraded in a normoxia environment, while in a hypoxic environment it binds to a hypoxia 
responsive element (HRE) and promotes transcription of genes.  Prolyl hydroxylase (PHD); von 
Hippel Lindau protein (pVHL); and ubiquitination (Ub) (262). 
 
Under normal oxygen conditions, PHDs in the presence of O2 hydroxylates HIF-
1α, which can then bind to von Hippel Lindau protein (Figure 1.17).  This event promotes 
the polyubiquitination of HIF-1α followed by its degradation (263).  In well-oxygenated 
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cells, HIF-1α is an exceptionally short-lived protein with a half-life of less than 5 minutes 
(264).  On the other hand, under hypoxic conditions, the lack of oxygen prevents the 
hydroxylation of HIF-1α by PHD, leading to its stabilization (Figure 1.17).  The lack of 
oxygen results in HIF-1α migrating to the nucleus where it dimerizes with HIF-1β which 
then binds the cofactor p300/CBP.  This HIF-1 complex is then able to bind to and induce 
the transcription of genes containing hypoxia responsive elements in their promoter 
region (262, 263).  Hypoxia is associated with the activation of several stress-induced 
protein kinases, including JNK, p38, ERK and the NF-κB pathways which trigger cell 
death (255, 265, 266).  NF-κB is a master regulator of inflammation response and 
controls the transcription of many pro-inflammatory cytokines like TNF-α and IL-1β 
which are increased in hypoxic tissues (267). 
Impaired placental perfusion in early development can lead to hypoxia in the 
placenta which often causes fetal growth restriction and in severe cases even fetal death 
(98, 268).  Normally, in early pregnancy, placentation occurs in relatively hypoxic 
conditions which is critical for proper placental and embryonic development (268).  
Hypoxia is needed to express adequate amounts of a variety of genes, including VEGFA, 
glycolytic enzymes and inducible nitric oxide synthetase (269).  Similarly, placental 
insufficiency (i.e. reduced placental blood flow) causes a chronic state of fetal hypoxemia 
and hypoglycemia.  As a result, endocrine and metabolic adaptations in the placenta, 
including the interaction between the Igf2 gene in feto-placental tissues and nutrient 
transporter genes in placental tissues, conserve fetal nutrients (270).   
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Glucocorticoids: 
Maternal obesity not only increases hypoxia and oxidative stress in tissues but 
also stimulates the production of adrenal glucocorticoids (271).  Physiological 
glucocorticoids (cortisol in humans, corticosterone in rats and mice) are synthesized in 
the adrenal cortex (272).  Cortisol synthesis is regulated by the activity of the 
hypothalamic–pituitary–adrenal (HPA) axis with adrenocorticotropin hormone (ACTH) 
stimulating cortisol production by the adrenals.  Cortisol, in turn, reduces corticotropin 
releasing hormone (CRH) and ACTH release by the hypothalamus and pituitary.  Cortisol 
produced by the mother, is transported to the placenta which regulates fetal exposure to 
glucocorticoids.  Glucocorticoid receptors are found in the placenta as well as most fetal 
tissues and are members of the nuclear hormone receptor superfamily of ligand-activated 
transcription factors (273, 274).  In the placenta, glucocorticoid receptors are thought to 
mediate both metabolic and anti-inflammatory effects (274) and increased levels of 
glucocorticoids in the placenta directly affect placental size (275).   
The ability of the placenta to inter-convert glucocorticoids between their active 
and inactive forms cortisol was first described by Osinski (276) in 1960.  In the placenta, 
there are two enzymes, 11β hydroxysteroid dehydrogenase type 1 (11β-HSD1) and type 2 
(11β-HSD2), that regulate the amount of circulating glucocorticoids in the body, 
specifically the active form cortisol (Figure 1.18).  Both 11β-HSD1 and 11β-HSD2 are 
members of the short-chain alcohol dehydrogenase superfamily (277) with the genes 
encoding them being found on chromosome 1 (278) and chromosome 16 (279), 
respectively.  The enzyme 11β-HSD1 catalyzes the bidirectional conversion of active-
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cortisol and inactive-cortisone activities, but operates predominately as an oxoreductase, 
converting cortisone to cortisol, due to its higher affinity for cortisone (Figure 1.18) 
(280).  In contrast, 11β-HSD2 is a high-affinity unidirectional enzyme that exhibits only 
oxidase activity, cortisol to cortisone, under physiological conditions and is regulated by 
oxygen (268, 281).  Interestingly, Mericq et al. (282) found 11β-HSD2 enzyme activity in 
the placenta to be is seven- to eightfold higher compared with the activity of 11β-HSD1.   
 
Figure 1.18.  Enzymatic Regulation of Glucocorticoids.  Hsd11b1 is responsible for the 
conversion of ‘inactive’ cortisone to ‘active’ cortisol while Hsd11b2 converts ‘active’ cortisol to 
‘inactive’ cortisone. 
 
Glucocorticoids are essential for the development and maturation of fetal organs 
(lung, thymus, gastrointestinal tract, heart, liver, and kidneys) at the end of gestation 
(283-287).  However, excessive exposure to glucocorticoids during earlier stages of 
development leads to altered maturation of organs as well as has a negative impact on 
fetal growth resulting in IUGR (286).  Normally the fetus has much lower levels of 
physiological glucocorticoids than its mother (288), with the concentrations being very 
high in maternal blood during pregnancy.  The placenta cannot stop lipophilic steroids 
from crossing to the fetus and therefore limiting embryonic exposure to cortisol is 
dependent on placental 11β-HSD2 concentration/activity which rapidly inactivates 
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cortisol to inert cortisone (Figure 1.19) (289, 290).  Even though 11β-HSD2 forms a 
potent barrier to the high levels of maternal glucocorticoids, approximately 10-20% of 
the maternal glucocorticoids are still able to cross intact to the fetus which are required 
for the development and maturation of fetal organs (289, 291).  Also, the barrier function 
of 11β-HSD2 is found to decrease in the last part of gestation, along with an increase in 
11β-HSD1 gene expression, which may be a mechanism by which cortisol concentrations 
rise at term to regulate fetal maturation and activate pathways associated with labor (206, 
292).  Alfaidy et al. (268) showed that oxygen may be an important regulator of placental 
11β-HSD2.  Indeed, hypoxia has been shown to modulate placental 11β-HSD2 levels by 
diminishing its promoter activity and down-regulating its protein synthesis (293, 294) 
while an increase in oxygen levels up-regulates glucocorticoid metabolism through 11β-
HSD2 activation.  There are also some indirect factors, TNF-α and IL-1β, which have 
been shown to decrease 11β-HSD2 activity in the placenta (256, 267). 
When the placenta exhibits reduced 11β-HSD2 activity there is an increase in 
fetal exposure to cortisol which is correlated to abnormalities in organ development.  For 
example, reduced 11β-HSD2 activity is associated with increased blood pressure as well 
as the programming of permanent hyperglycemia in the offspring during adult life (295, 
296).  Similarly, in humans, mutations in the 11β-HSD2 gene have been associated with 
low birth weight and reduced 11β-HSD2 activity, and increased fetal cortisol levels have  
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Figure 1.19.  Glucocorticoid Signaling between the Mother, Placenta and Fetus.  Activation 
of the maternal hypothalamic–pituitary–adrenal (HPA) axis during pregnancy leads to increased 
circulating levels of cortisol (filled circles).  Maternal cortisol is transported to the placenta where 
it is either broken down by the enzyme HSD2 into inactive cortisone (grey triangles) or passes 
directly through to the fetus. If there is not enough HSD2 in the placenta it can lead to fetal HPA 
axis activation (associated with low birthweight, metabolic and brain abnormalities). 
Corticotropin releasing hormone (CRH); adrenocorticotropin hormone (ACTH); and 11β 
hydroxysteroid dehydrogenase type 2 (HSD2) (297). 
 
been reported in association with IUGR (Figure 1.19) (272).  Overall, fetal exposure to 
high levels of glucocorticoids reduces fetal growth independent of its effects on maternal 
food intake as well as alters the trajectory of fetal tissue maturation (131).  Interestingly, 
placental glucocorticoid metabolism differs according to sex of the fetus with the male 
fetus being less sensitive to the effects of glucocorticoids compared to the female fetus 
(298).    
48 
 
Conclusion 
Obesity impacts not only the health of the mother but when combined with 
pregnancy is associated with an increased risk for their offspring to be obese and develop 
metabolic syndrome.  Offspring from obese dams are more likely to experience IUGR 
which if accompanied by a catch-up growth in the first few weeks after birth has been 
correlated to alterations in adult organ function.  Interestingly, the extent of the 
alterations may be sex dependent, but more research is needed to determine the exact 
mechanisms that are impacting gender-dependent alterations in organ development.  Of 
special interest is the impact of maternal obesity on skeletal muscle development given 
that it is an important metabolic organ.  Currently, there is a gap in understanding how 
maternal nutrition affects early muscle differentiation; although, a number of studies have 
documented a negative effect of maternal obesity on secondary and tertiary myogenesis 
and the metabolic function of this skeletal muscle.   
The intrauterine growth of a fetus is largely determined by the capacity of the 
placenta, which is a key organ in respiratory gas, nutrient, and waste exchange, to supply 
nutrients from the mother to the fetus.  Normal levels of oxygen tension and ROS are 
needed in the placenta for proper development to occur.  However, oxidative stress, 
hypoxia and altered glucocorticoid metabolism in the placenta inhibit the transport of 
nutrients which can negatively impact fetal development.  The placenta is unique in that 
it is able to produce an adaptive response if the fetus is not developing well; however, 
this adaptation can only partly compensate for impaired growth in utero.   
49 
 
While the normal development of the placenta and muscle is well described, the 
mechanisms by which maternal obesity alters this development are unknown.  The long-
term goal of our laboratory is to understand how maternal obesity alters placental 
function and impacts cell differentiation during embryonic/fetal development.  The 
working hypothesis of this project is that maternal obesity induces placental hypoxia 
and/or oxidative stress resulting in the altered differentiation of somite-associated 
mesodermal cells and reduced skeletal muscle development.  In order to test this 
hypothesis, the lethal yellow (LY) mouse model of obesity was used.  The LY mouse has 
a deletion mutation on the C57BL/6 (B6) background which results in ectopic expression 
of agouti (Figure 1.20).  Agouti, in turn, inhibits hypothalamic signaling of -MSH and 
CART via the melanocortin 4 receptor (MC4R) resulting in inhibition of satiety, excess 
caloric intake, and progressive obesity.  In this study, mid-gestation embryos and 
placentas that were developed in a B6 (lean) or LY (obese) environment were examined 
for placental abnormalities and differences in embryonic cell differentiation, specifically 
alterations in primary myogenesis.  
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Figure 1.20.  Lethal Yellow Mouse Model of Obesity.  Schematic representation of the deletion 
mutation on the C57 BL/6 background which produces the Lethal Yellow phenotype.   
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CHAPTER II 
Maternal Obesity Alters Embryonic Expression of Desmin and PPARγ, Reduces 
Placental Function and Alters Placental Expression of Stress-Related Genes  
Kristin A. Norwood, Amanda K. Brandt and Jennifer R. Wood 
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, NE 
 
ABSTRACT 
Maternal obesity has been correlated to decreased skeletal muscle mass, increased 
adipose tissue mass and increased risk for metabolic syndrome in their children.  
However, mechanistic links between maternal obesity and the development of these 
phenotypes remain unclear.  Thus, the objective of the current study was to determine 
how maternal obesity alters the temporal program of skeletal muscle differentiation.  To 
achieve this objective, mid gestation embryos (12.5 days post coitus) were collected from 
age-matched, obese Lethal Yellow (LY) and normal weight C57BL/6 (B6) dams. As 
expected, the body weight of LY dams was heavier than B6 dams while the average wet 
weight and tail somite number of LY-derived embryos was decreased.  To determine the 
impact of maternal obesity and decreased embryo weight on mesodermal cell 
differentiation, the expression of the myogenic marker desmin (DES) and adipogenic 
marker PPARG were examined.  Surprisingly, DES expression tended to be increased (P 
< 0.09) in somite-associated cells of LY-derived embryos.  Furthermore, PPARG 
expression was predominately localized to the neural tube and was significantly 
decreased (P < 0.04) in LY-derived embryos.  Placental function in the LY dams was 
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also altered.  Specifically, the ratio of embryo to placenta weight was decreased 12% in 
LY-derived embryos suggesting abnormalities in placental development.  Furthermore, 
the mRNA abundance of Hif1a, Pecam1, and Hsd11b2 was altered in the placenta 
indicative of chronic hypoxemia and stress.  Taken together, these data demonstrate that 
temporal regulation of myogenesis is altered in embryos derived in an obese environment 
and may be associated with obesity-induced placental stress. 
 
Key Words: Obesity, Cortisol, Muscle Development, Neural Tube 
 
INTRODUCTION 
Obesity is a considerable public health problem that is associated with an 
increased risk of several chronic diseases including type 2 diabetes and cardiovascular 
disease (1, 2).  The prevalence of obesity worldwide is 15–20% with at least 1/3 of 
reproductive age women classified as obese in the United States (3, 4).  Maternal obesity 
negatively affects the infant’s health by increasing fetal adiposity as well as increasing 
the lifetime risk of obesity and development of metabolic syndrome during childhood or 
early adult life (5-7).  Specifically, maternal obesity increases fetal intramuscular 
adipocytes and fibrosis (8-10) as well as decreases muscle fiber density (11).   
Furthermore, Yan et al. (12) have shown attenuated insulin signaling in the skeletal 
muscle of offspring derived from over nourished mothers.  
These changes in the structure and function of skeletal muscle (12, 13) suggests 
that the activation and/or regulation of the skeletal muscle program are altered when the 
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fetus is exposed to an obese in utero environment.  During normal fetal development, 
skeletal muscle in the trunk and limb develops from stem cells in the dermomyotome 
layer of the somite which differentiate into myogenic progenitor cells upon stimulation of 
paired box (Pax) 3 and Pax7 expression (14).  PAX3 and PAX7 are transcription factors 
that regulate  the expression of myogenic factor-5 (Myf5), myogenic differentiation 1 
(MyoD), myogenin (Myog), and desmin (Des) which, in turn, promote differentiation of 
proliferating muscle progenitor cells into myocytes and ultimately mature muscle fibers 
(15-19).  Regulation of the myogenic program is dependent on multiple signals from the 
neural tube located adjacent to each somite and neural crest cells which migrate around 
and within the somite (20, 21).  Together, these signals maintain an important balance 
between the maintenance and/or migration of stem and progenitor cells and the 
differentiation and establishment of mature myofibers which are the major components of 
adult skeletal muscle.   
The effect of maternal obesity on fetal development is mediated by the placenta 
which serves as a dynamic interface between the mother and developing fetus (22).  
Hayes et al.(23) showed that excessive adiposity during pregnancy results in increased 
platelet endothelial cell adhesion marker (PECAM1) and decreased smooth muscle actin 
expression, indicative of poor placental vascularization.  Decreased placental vascular 
density has been tied to reduced tissue oxygenation and the development of a hypoxic 
environment (24).  Poor development of placental vasculature also results in reduced 
placental blood flow, leading to not only a smaller placenta but also insufficient nutrient 
transport (25, 26).  Hypoxia, in turn, can induce oxidative stress due to decreased 
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expression of antioxidants (27) as well as decreased expression of 11-hydroxysteroid 
dehydrogenase 2 (Hsd11b2) which converts glucocorticoids from an active to inactive 
state (28).  Collectively, these maternal obesity dependent changes to placental function 
have been linked to intrauterine growth restriction (IUGR).  Furthermore, activation of 
signaling pathways due to hypoxia and oxidative stress as well as changes to DNA 
methylation and histone modifications by the glucocorticoid, cortisol, result in changes in 
the fetal program which can directly impact phenotypes expressed by the children of 
obese mothers (29-31).     
Taken together, these data indicate that the increased incidence of maternal 
obesity may perpetuate the obesity epidemic in the next generation due in part to altered 
skeletal muscle programming.  However, mechanistic links between maternal obesity and 
the regulation of the skeletal muscle program during embryonic development remain 
poorly defined.  In the current study, the Lethal Yellow (LY) mouse model was used to 
identify maternal obesity-dependent temporal and/or spatial changes in primary 
myogenesis.  The LY mouse has a deletion mutation on the C57BL/6 (B6) background 
which results in ectopic expression of agouti (32-34).  Agouti, in turn, inhibits 
hypothalamic signaling of -MSH and CART via the melanocortin 4 receptor (MC4R) 
resulting in inhibition of satiety, excess caloric intake, and progressive obesity (35).  We 
have previously demonstrated that the obese phenotype of LY females includes a 
significant increase in total body weight, visceral fat weight, and circulating leptin and 
insulin concentrations (36).  Using this model, we have identified novel differences in the 
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expression of myogenic markers and abnormalities in placental function of mid-gestation 
embryos collected from lean (B6) and obese (LY) dams.     
MATERIALS AND METHODS 
Animal Model:  Founder B6 (C57BL/6 a/a) and LY (C57BL/6 Ay/a) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME).  Fertile, male B6 mice were 
mated with aged-matched (17-week-old) B6 or LY female littermates.  Twelve days after 
visual confirmation of a vaginal plug (i.e., 12.5 dpc), B6 (n=7) and LY (n=12) dams were 
euthanized and maternal weights were determined.  Viable and degenerative embryos 
were collected from each dam (degenerative: B6=7.01% and LY=5.53%).  Each viable 
embryo and its placenta were weighed and the number of tail somites per embryo counted 
from hind limb to the tip of the tail.  Half of the embryos from each litter were fixed in 
Bouin’s solution and embedded in paraffin for morphological and immunohistochemical 
(IHC) analyses while the other half were flash frozen for RNA extraction.  All of the 
placentas were flash frozen for RNA extraction.  Agouti mRNA abundance (see QPCR 
methods below) was used to distinguish between B6 and LY embryos derived from LY 
dams.  All animal experiments were approved by the University of Nebraska-Lincoln 
Institutional Animal Care and Use Committee. 
Reverse Transcription:  Whole placenta and whole embryo RNA was isolated 
using Tri-Reagent (Invitrogen, Carlsbad, CA).  RNA (5 μg) from each individual sample 
was treated with DNase I (Promega, Madison, WI) and reverse transcribed using random 
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hexamer primers (Roche Diagnostics, Indianapolis, IN) and Moloney Murine Leukemia 
Virus reverse transcriptase (Promega) according to manufacturer’s instructions. 
Quantitative, Real-Time PCR (QPCR):  Forward and reverse primers for 
candidate genes and the housekeeping gene β-actin (Actb) (Table 2.1) were designed 
(Primer Express, Applied Biosystems, Foster City, CA) and synthesized (Integrated DNA 
Technologies, Coralville, IA).  Primers were tested empirically to determine the maximal 
concentration that produced specific amplification of the target sequence in the absence 
of primer dimers.   Quantitative PCR (QPCR) reactions were carried out using each 
primer set and equivalent amounts of cDNA from each sample as previously described 
(37).   QPCR amplification of Gapdh and 18s rRNA was carried out using an endogenous 
control kit (Applied Biosystems, Foster City, CA). The relative abundance of the 
candidate mRNA in each sample was normalized using the most stably expressed 
housekeeping gene(s) (Gapdh, 18s, or Actb) which was determined using Normfinder 
(38).  Specifically, embryo candidate genes were normalized using the geometric mean of 
18s rRNA and Gapdh mRNA abundance for each embryo sample while Gapdh mRNA 
abundance was used to normalize candidate genes for each placenta sample.  The 
resulting normalized data for each candidate mRNA was then compared to the mean 
normalized mRNA abundance in B6-derived placenta or embryo and expressed as a fold 
change. 
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Table 2.1. Primer Sequences for QPCR Analysis 
 
Immunofluorescence Analyses:  Transverse sections (8 µm) were generated from 
the Bouin’s-fixed embryos from LY and B6 dams for IHC analyses.  Samples were 
deparaffinized and hydrated followed by boiling in 10 mM sodium citrate for antigen 
retrieval (39).  Samples were blocked in 1X PBS, 5% normal goat serum and 0.3% Triton 
X-100.  After blocking, anti-DES (1:200) (Abcam, Cambridge, MA), anti-PPARG 
(1:200) (Cell Signaling, Danvers, MA), or no primary antibody diluted in SignalStain 
Antibody Diluent (Cell Signaling, Danvers, MA) was added to each section and 
incubated overnight at 4°C.  Sections were washed and subsequently incubated with 
Alexa Fluor 555 anti-rabbit secondary antibody (DES) or Alexa Fluor 488 anti-rabbit 
secondary antibody (PPARG) (Cell Signaling, Danvers, MA).  Sections were washed and 
mounted with VectaShield Hard Mount containing DAPI (Vector Labs, Burlingame, CA) 
to stain cell nuclei.  Sections exposed to only Alexa Fluor 555 or Alexa Fluor 488 anti-
rabbit secondary antibodies were used as a negative control in order to ensure specific 
detection of signal.  Detection of DES or PPARG positive cells was carried out using an 
IX71 Olympus inverted brightfield and fluorescence microscope (Hitschfel Instruments, 
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Inc., St. Louis, MO) and images captured using the Slidebook 4.2 Software (Intelligent 
Imaging Innovations, Inc., Denver, CO) (40).  Images were captured using the same 
exposure length and analyzed using Image J Software (National Institute of Health, 
Bethseda, MD) for the percent area stained.  The mean value for embryos derived in LY 
dams was compared to the mean value from embryos derived in B6 dams and shown as a 
fold change.   
Statistical Analyses:  All statistical analyses were carried out using GraphPad 
Prism 5.0 (GraphPad Software, La Jolla, CA).  Statistically significant differences in 
weights, mRNA abundance or protein expression between B6 and LY dams or B6- and 
LY-derived embryos or placentas (P < 0.05) were determined using Student t-test.   
RESULTS 
Maternal Obesity Reduces Fetal Growth and Induces Modest Developmental 
Delays in Viable Fetuses:  As expected based on our previous study (36), maternal body 
weights of female LY mice were significantly higher (P < 0.0001) than age-matched B6 
mice at embryonic day 12.5 (E12.5) (Figure 2.1A).  While there was an increase in body 
weight, no difference in litter size of viable embryos (Figure 2.1B) or the number of 
degenerating embryos (data not shown) was identified.  Individual wet weights of the 
viable embryos showed a significant 30% reduction (P < 0.0001) in LY-derived 
compared to B6-derived embryos (Figure 2.1C).  Furthermore, embryos derived from LY 
dams had a modest but significant reduction (P < 0.0001) in tail somite number      
(Figure 2.1D).  To establish that these morphological effects were due to the maternal 
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obese phenotype and not overexpression of agouti, B6 and LY embryos collected from 
LY dams were compared.  There was no difference in embryo and placental wet weights 
or tail somite number (Supplemental Figure 2.7) between LY and B6 littermates.  All 
placentas from LY dams, regardless of embryo phenotype, expressed agouti.  Agouti can 
bind to the melanocortin family of receptors including MC1R and MC4R; however, there 
were negligible levels of Mc1r and Mc4r mRNA detected in either the placentas or 
embryos collected from LY dams (data not shown).  Together, these data indicated that 
the embryonic phenotypes are induced by the obese phenotype of the dams and not the 
ectopic expression of 
agouti.  The 
embryonic phenotypes 
are consistent with 
IUGR and modest 
developmental delays 
reported in diet 
induced obesity 
models (22, 41, 42).   
 
 
                             
Figure 2.1. LY Mice Exhibit an Obese Phenotype and Altered Growth of their Embryos.  
Maternal body weight (A) and the number of embryos at 12.5 dpc (B) were determined for B6 
(black bar, n=7) and LY (yellow bar, n=12) dams.  The wet weights (C) were recorded for 
embryos (B6-derived, black bar, n=63; LY-derived, yellow bar, n=113) and the number of tail 
somites (D) for each B6-derived (black bar, n=58) or LY-derived (yellow bar, n=103) embryo 
were counted from hind limb to tip of the tail.  The mean ± SEM normalized values are presented, 
and asterisks represent a statistically significant difference in means (P < 0.0001, ***). 
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Primary Myogenesis is Accelerated in Embryos Developed in an Obese In Utero 
Environment:  To assess differences in myocyte development between LY- and B6-
derived embryos, IHC analysis of DES expression was carried out.  DES is a marker of 
differentiating myocytes and, upon its expression, myocytes are destined to complete 
myogenesis (i.e. this is an irreversible differentiation step).  As expected, DES-positive 
cells were located exclusively in the somite regions adjacent to the neural tube in both 
B6- and LY-derived embryos (Figure 2.2A and 2.2B).  In contrast, there was no signal 
detected in sections incubated with only secondary antibody (NEG Control, Figure 2.2A). 
   
Figure 2.2. DES Expression is Increased in the Somite in LY-Derived Embryos.  (A, B) 
Immunofluorescent detection of DES was carried out using transverse sections of 12.5 dpc 
embryos derived from B6 and LY dams.  Representative images (A=40X, B=100X) are shown 
for DES (orange) and DAPI (blue) expression.  Sections processed without primary antibody 
were used to verify specific detection of DES (NEG control).  (C) The percent of the indicated 
area (circled in A) which is positive for DES was determined for each sample (B6, black bar, 
n=8; LY, yellow bar, n=11), normalized to the average percent area for the B6-derived embryos, 
and expressed as a fold change (mean ± SEM).  The mean ± SEM normalized values are 
presented and the data was tested for statistical significance (P < 0.09, †).  Scale bars=100 µm 
(A) and 50 µm (B). 
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The percentage of DES-positive cells in LY- compared to B6-derived embryos was also 
different.  However, there tended to be 2-fold more DES-positive cells (P < 0.09) in LY-
derived embryos (Figure 2.2C) which was unexpected given that fetal and adult muscle 
mass is decreased in other models of maternal obesity (11, 13, 43, 44).   
PPARG is Predominately Expressed in the Neural Tube and Its Expression is 
Decreased in LY-Derived Embryos:  Myocytes and adipocytes arise from the same stem 
cells in vitro (43).  Therefore, given the difference in DES expression in LY-derived 
embryos, we also examined the expression of a marker of adipocyte differentiation, 
peroxisome proliferator-activated receptor gamma (PPARG), in each embryo (Figure 2.3, 
2.4).  While some PPARG-positive cells were identified in the somites of both LY- and 
B6-derived embryos, PPARG expression was primarily localized to the neural tube of 
each embryo (Figure 2.3A-D).  Conversely, no signal was detected in sections incubated 
with only secondary antibody (NEG control, Figure 2.3E).  Furthermore, PPARG was 
expressed in cells that appeared to be delaminating from the neural tube (Figure 2.4). 
Semi-quantitative analysis of PPARG expression in the somite region revealed no 
differences in the percentage of PPARG positive cells in B6- or LY-derived embryos (1.0 
± 0.50 vs. 0.66 ± 0.27, P = 0.52).  However, we did detect a significant 2-fold decrease (P 
< 0.04) in PPARG expression in the neural tube region (circled regions; Figure 2.3A and 
C) of LY-derived embryos (Figure 2.3F).   
82 
 
 
Figure 2.3. PPARG Expression is Decreased in the Neural Tube of LY-Derived 12.5 dpc 
Embryos.  Representative embryos (40X) from B6 and LY dams were stained for 
immunofluorescent detection of PPARG (green) and DAPI (blue).  A representative section 
processed without primary antibody served as a negative control (E) to verify specific detection 
of PPARG.  The percent of the indicated area (circled in A, C) which is positive for PPARG was 
determined for each sample (B6, black bar, n=8; LY, yellow bar, n=11), normalized to the 
average percent area for the B6-derived embryos, and expressed as a fold change (mean ± SEM).  
Asterisk represents a statistically significant difference in means (P < 0.05, *). Scale bars=100 
µm. NT=neural tube and Som=somite. 
 
Figure 2.4. PPARG is Expressed in Cells Adjacent to the Neural Tube in 12.5 dpc Embryos.  
Representative images (100X) of B6 (n=8) and LY-derived embryos (n=11) from Figure 3 
showing expression of PPARG (green).  Arrows indicate PPARG-positive cells adjacent to the 
neural tube.  Scale bars=50 µm. NT=neural tube. 
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Expression of the Epithelial-Mesenchymal Transition Marker Zeb2 is Decreased 
in Embryos Developed in an Obese In Utero Environment:  The conversion of neural 
tube cells from an epithelial to a mesenchymal lineage is an important process prior to 
delamination and migration of these cells during embryonic development.  Furthermore, 
there is in vitro evidence that PPARG regulates the epithelial to mesenchymal transition 
(EMT) (44, 45).  Therefore, to determine if decreased neural tube expression of PPARG 
was associated with changes in the mRNA abundance of transcription factors that 
regulate EMT (SNAI1, SNAI2, TWIST1, ZEB2), QPCR was carried out using RNA 
collected from the whole 
embryo.  While there were 
no differences in the 
mRNA abundance of 
Snai1, Snai2, or Twist1; 
Zeb2 tended to be 
decreased 1.35-fold (P < 
0.07) in LY- compared to 
B6-derived embryos 
(Figure 2.5). 
Figure 2.5. Abundance of EMT mRNAs in Whole Embryos from B6 and LY Mothers.  
QPCR analysis of Snai1, Snai2, Twist1 and Zeb2 was carried out.  The normalized, relative 
abundance of each gene from embryos derived in LY dams (yellow bar, n=10) was compared to 
the mean, normalized relative abundance of each gene from embryos derived in B6 dams (black 
bar, n=10) and the data shown as a fold change (mean ± SEM).  The data was tested for statistical 
significance (P < 0.1, †).   
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Reduced Placental Growth and Altered Gene Expression in LY-derived Placenta:  
Given that the placenta serves as a critical interface between the dam and fetus, the effect 
of maternal obesity on placental function was examined.    The placental weight was 
significantly reduced (P < 0.0001) when collected from LY compared to B6 dams (Figure 
2.6A).  Furthermore, there was a 12% decrease (P < 0.02) in the ratio of embryo to 
placenta weight when embryos were collected from LY dams (Figure 2.6A) suggesting 
abnormalities in placental development and/or function.  To determine if the placentas 
collected from LY dams exhibited evidence of hypoxemia, the mRNA abundance of 
hypoxia induced transcription factors Hif1a and Arnt were determined by QPCR.  While 
Hif1a mRNA abundance was modestly increased (1.24-fold, P < 0.07), there was no 
difference in Arnt expression (Figure 2.6B).  In addition to these transcription factors, 
markers of angiogenesis which are increased upon hypoxia were also examined.  The 
mRNA abundance of Pecam1 was increased 1.34-fold (P < 0.05) in placenta from LY 
compared to B6 dams (Figure 2.6C).  However, the mRNA abundance of other 
angiogenesis makers including  Angpt1, Vcam1, or Vegfa_164 was not different in LY 
compared to B6 placentas.  Chronic hypoxemia can also impact the expression of 
enzymes which regulate the conversion of glucocorticoids between their inactive 
(Hsd11b2) and active (Hsd11b1) isoforms.  There was no difference in Hsd11b1 mRNA 
abundance in placentas derived from B6 and LY dams.  However, Hsd11b2 mRNA 
levels were decreased 1.59-fold (P < 0.04) (Figure 2.6D).   
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Figure 2.6. Placental Morphology and Function is Altered in LY Dams.  Wet weights (A) 
were recorded for B6-derived (black bar, n=27) and LY-derived (yellow bar, n=73) placenta as 
well as the ratio of embryo to placenta weight was determined.  (C, D) QPCR analysis of Hif1a, 
Arnt, Angpt1, Pecam1, Vcam1, Vegfa_164, Hsd11b1 and Hsd11b2 was carried out.  The 
normalized, relative abundance of each gene in placenta from LY dams (yellow bar, n=12) was 
compared to the mean, normalized relative abundance of each gene from placenta from B6 dams 
(black bar, n=11) and the data shown as a fold change (mean ± SEM).  The data was tested for 
statistical significance (P < 0.1, †; P < 0.05, *; and P < 0.0001, ***). 
 
DISCUSSION 
Numerous studies have demonstrated a clear correlation between maternal obesity 
and altered physiological function in adult offspring.  Indeed, maternal overnutrition has 
been linked to decreased density and/or metabolic function of fetal and adult skeletal 
muscle in sheep (11, 12, 46, 47) and rodents (48, 49).  Based on in vitro studies of 
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mesodermal stem cells and in vivo studies carried out in the last third of gestation, one 
underlying mechanism of this phenotype could be decreased development of skeletal 
muscle and increased development of adipose tissue from common stem or progenitor 
cells (13, 43).  However, data in the current study indicates that maternal obesity 
increased DES expression in the dermomyotome layer of somites in mid-gestation 
embryos suggesting increased differentiation of skeletal muscle cells.  Furthermore, at 
mid-gestation, PPARG expression was primarily localized to the neural tube with very 
little expression in the somite indicating temporal uncoupling of myogenesis and 
adipogenesis. Thus, for the first time, we provide evidence that maternal obesity 
increases myogenesis early in development and suggest that these events may cause 
changes in the trajectory of skeletal muscle progenitor cell differentiation.  This may 
subsequently result in reduced skeletal muscle development later in gestation and reduced 
muscle mass and/or function in adult offspring.   
Primary myogenesis is initiated in the early embryo (E8.5-E9.0 in the mouse) and 
results in the differentiation of stem cells into myoblasts which proliferate, migrate, and 
ultimately fuse to form primary myotubes (i.e., primitive muscle fibers) (50).  The 
intermediate filament protein, Des, is initially expressed in proliferating myoblasts and its 
expression is maintained through differentiation into mature myofibers (51-53).  DES 
expression in the somite is detected at E9.0, with cranial somites exhibiting expression 
first followed by caudal somites.  Interestingly, we showed that expression of DES in the 
dermomyotome layer of the somite is increased in E12.5 embryos developed in an obese 
compared to a normal weight environment.  This difference in expression was not 
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attributed to differences in the expression profile of cranial versus caudal somites as each 
embryo was processed to ensure that somites at similar anatomical positions were 
examined.  Li et al. (54) showed that loss of DES expression in the C2C12 myoblast cell 
line results in poor fusion of myoblasts into myotubes suggesting that one function of 
DES is to promote myotube formation over myoblast proliferation and/or migration.  In 
sheep, decreases in muscle fiber density were identified in both the semitendinosus (limb) 
and longissimus dorsi (trunk) muscles (10-12) indicating an overall reduction in myotube 
formation.  Based on these collective data, we hypothesize that maternal obesity favors 
myoblast exit from the cell cycle and fusion during primary myogenesis resulting in 
decreased myoblast proliferation.  
PPARG is a well described transcriptional regulator of adipocyte differentiation 
and is expressed in the committed preadipocyte and mature white adipocyte (55).  Given 
this role of PPARG and evidence that adipocytes and myocytes arise from common 
mesodermal stem cells in vitro (43), we anticipated that PPARG expression would be 
localized to the somite and be increased in embryos derived from LY dams.  In contrast, 
however, PPARG expression was primarily localized to the ventral neural tube at E12.5 
and the percentage of PPARG-positive cells was decreased in the neural tube of embryos 
developed in an obese environment (Figure 2.3).  These data are consistent with PPARG 
localization studies during development carried out by Michalik et al. (56).  Likewise, 
Wada et al. (57) showed high levels of PPARGexpression in the embryonic brain and 
demonstrated that PPARG is required for neural stem cell proliferation and the formation 
of neurospheres in vitro.  The novel decrease in PPARG upon maternal obesity identified 
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in the current study suggests that, not only is PPARG functionally important during 
neural development, but also provides the first evidence that decreased PPARG may 
contribute to abnormalities in neural development in an obese environment.   
Irrespective of the role of PPARG in the neural tube, the lack of PPARGpositive 
cells in the somite of mid-gestation embryos (Figure 2.3) indicates that temporal 
regulation of primary myogenesis and adipogenesis are uncoupled.  While these findings 
oppose in vitro studies which show that adult mesenchymal stem cells divergently 
differentiate into myogenic versus adipogenic cells (58), mechanistic differences between 
embryonic cell differentiation during in vivo development and adult stem cell 
differentiation during tissue regeneration are not unprecedented.  For example, 
regeneration of skeletal muscle, which includes activation of satellite cells, in the adult 
animal is mechanistically different from the myogenic program during embryonic 
development (59, 60).  Thus, given the metabolic importance of the skeletal muscle to 
adipose tissue ratio in the adult animal, a better understanding of how adipogenesis is 
stimulated and regulated during normal embryo and fetal development is needed.  
Interestingly, Billon et al. demonstrated that neural crest cells have the potential to 
differentiate into adipocytes (61).  Likewise, we detected PPARGexpression in cells that 
may be delaminating from the neural tube and therefore may represent neural crest cells 
(Figure 2.4).  However, while adult adipose tissue in the head and neck have been traced 
to a neural crest cell lineage, fat pads in the trunk including perigonadal, subcutaneous, 
and perirenal depots were not derived from the neural crest cell lineage (61).  These data 
indicate that different adipose tissue depots likely develop by unique mechanisms and 
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arise from different stem and progenitor cell lineages during development adding another 
layer of complexity to adipose tissue development.   
The specific mechanisms by which the maternal environment alters embryo 
growth and development are uncertain, but include changes in placental function.  
Indeed, in our model of maternal obesity, embryo weight, placenta weight, and the ratio 
of embryo to placenta weight were decreased (Figure 2.1 and 2.6) indicating potential 
abnormalities in placenta development and/or function.  The decrease in placenta and 
embryo weight at mid-gestation is consistent with other rodent models of maternal 
obesity or gestational diabetes (22, 41, 42).  However, an increased risk for macrosomia 
due to increased growth during gestation (large for gestational age, LGA) is the common 
phenotype reported upon human maternal obesity (62-64).  It is important to note that the 
rodent studies detected growth restriction at mid-gestation of pregnancy (E12.5-14.5) 
while most human studies are identifying small and large for gestational age babies at 
birth.  Furthermore, Jones et al. (65) showed that E18.5 fetuses from high-fat fed 
C57/BL6 dams weighed more than fetuses from control-fed dams due to increased 
placental transport of glucose and aminoisobutyric acid.  In our mouse colony, weaning 
weights of offspring from obese, LY dams were not different than age-matched offspring 
from lean, B6 dams (Wood, unpublished data).  Thus, restricted growth during the first 
half of gestation may be followed by compensatory growth during the second half of 
gestation ultimately resulting in normal or increased birth weights in the murine model of 
maternal obesity and may represent a mechanism of macrosomia development.   
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The abnormalities in fetal growth associated with maternal obesity have been 
correlated to placental inflammation and hypoxemia (7, 66, 67).  In the current study, we 
detected no evidence of inflammation (data not shown) but did detect indications of 
hypoxemia (Figure 2.6) in the placenta from obese LY dams.  Furthermore, we 
demonstrated that Hsd11b2 mRNA abundance was decreased in placenta from LY dams 
(Figure 2.6).  The 11-HSD type 2 enzyme converts active glucocorticoids to their 
inactive form and its expression in the placenta is crucial in order to limit transport of 
maternal cortisol to the fetus (28).  Interestingly, Gokulakrishnan et al. (68) showed that 
in utero exposure of rat fetuses to dexamethasone, a synthetic glucocorticoid, during the 
second half of gestation (E12-E22) resulted in reduced placenta and fetal weight, a 
decreased fetal-to-placenta weight ratio, and decreased protein mass in skeletal muscle of 
the quadriceps and diaphragm.  Furthermore, Nesan et al. (69) demonstrated that 
knockdown of the glucocorticoid receptor (GR) during early embryogenesis of zebrafish 
resulted in reduced embryo length but increased expression of Myog.  Together, these 
data indicate an important role of cortisol in regulating the myogenic program.   
In summary, we have presented novel evidence that maternal obesity-dependent 
increases in fetal exposure to hypoxemia and/or cortisol results in increased expression of 
the skeletal muscle differentiation marker DES during primary myogenesis.  Based on 
these data, we propose that primary myogenesis is precociously activated when the 
embryo develops in an obese environment resulting in depletion of skeletal muscle 
progenitor cells required for secondary myogenesis.  In addition, we have shown that 
PPARG expression is localized to the neural tube indicating a function for this 
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transcription factor independent of adipocyte development.  These key findings represent 
an important shift in our understanding of how maternal obesity reduces skeletal muscle 
fiber density and increases adipose tissue mass during development which will have long-
lasting effects on the metabolic health of their children.    
 
SUPPLEMENTAL FIGURE  
 
Supplemental Figure 2.7. Embryos from LY Mice Do Not Differ in Growth Regardless of 
Agouti Expression.  Embryos and their corresponding placenta were isolated from B6 dams (B6 
embryo, black bar, n=10) or LY dams (B6 embryo, grey bar, n=7; LY embryo, yellow bar, n=3).  
Wet weights for each embryo and placenta were recorded as well as the number of tail somites 
were counted (mean ± SEM).  Statistically significant differences (n.s., not significant; P < 0.1, †; 
P < 0.05, *; and P < 0.001, **) were determined using one-way ANOVA. 
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CHAPTER III 
Placenta from Obese, Lethal Yellow Dams Exhibit Reduced Weight and Show 
Evidence of Hypoxia and Abnormal Cortisol Metabolism but Not Oxidative Stress 
 Kristin A. Norwood and Jennifer R. Wood  
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, NE 
 
ABSTRACT 
Proper placental development is critical for adequate gas, nutrient, and waste 
exchange and ensures appropriate transfer of substrates needed to support normal fetal 
growth.  Previous studies demonstrate that maternal obesity negatively impacts placental 
function but the mechanisms have not been defined.  Thus, the objective of this study was 
to determine how maternal obesity impacts the overall growth and molecular phenotype 
of the mid-gestation placenta.  To achieve this objective, embryos and their 
corresponding placenta were collected 12.5 days post coitus from age-matched, obese 
Lethal Yellow (LY) and normal weight C57BL/6 (B6) dams.  Placenta weight and the 
ratio of embryo to placenta weight were decreased in LY-derived embryos suggesting 
abnormalities in placental development and/or function.  To determine if the reduced 
placental weight is associated with abnormalities in hypoxia, oxidative stress or 
glucocorticoid metabolism, whole placenta was collected for quantitative real-time PCR, 
Western blot, and enzyme activity assays. We identified significant changes in the 
mRNA abundance of Hif1a, Pecam1, Gpx1 and Hsd11b2 in the placenta of LY compared 
to B6 dams.   However, there were no differences in the expression of Sod1 or Sod2 and 
there was no increase in the expression or activity of xanthine oxidase.  The impact of 
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altered placental gene expression on embryonic gene expression was also examined.  
Interestingly, embryos from an obese environment displayed decreased mRNA 
abundance of Vegfa_164 and Vegfa_165b.  Taken together, the data provide evidence that 
maternal obesity increases placenta hypoxemia and reduces glucocorticoid metabolism 
which may be altering nutrient transport by the placenta and negatively impacting 
angiogenesis in the embryo.   
 
Key Words: obesity, placenta, hypoxia, glucocorticoids 
 
INTRODUCTION 
Obesity in the USA is a rising epidemic with 27.8% of the total USA population 
considered obese in 2011 (1).  Furthermore, approximately 35% of reproductive aged 
women are obese which translates to more than one in five pregnant women being obese 
(2, 3).  Excess weight gain during pregnancy has detrimental effects on offspring 
development as well as their future health (4).  During development, nutrient availability 
and fetal growth are dependent on maternal nutrient availability which is transported via 
the placenta.  Specifically, the placenta’s role is to regulate the respiratory gas, nutrient, 
and waste exchange between the mother and developing fetus (5-9). 
The placenta is the first organ to develop during mammalian embryogenesis and 
forms from trophoblast cells, which provide the main structural and functional 
components needed to bring the fetal and maternal blood systems into close contact (10).  
Normal placental angiogenesis is critically important to ensure adequate blood flow to the 
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placenta and therefore, to provide the substrates that support normal fetal growth (11).  
Reduced oxygen levels and the synthesis of reactive oxygen species (ROS) which are 
associated with abnormal functions in other physiological systems play an important role 
in normal placenta development.  For example, during early pregnancy, placentation 
occurs under low oxygen tension conditions which promote placental morphogenesis, 
angiogenesis, and cell fate decisions critical for proper placental development (12, 13).  A 
moderate increase in ROS levels is also a normal occurrence in the placenta during the 
second trimester of pregnancy which leads to the stimulation of cell growth and 
proliferation (14, 15).  The development of the placenta and its functions during gestation 
are dynamic processes which are influenced by maternal diet, body composition and 
lifestyle (7, 16).  Increased maternal nutrition or environmental stress results in abnormal 
placental angiogenesis and altered fetal growth (6, 11).  Likewise, hypoxia and oxidative 
stress associated with maternal obesity inhibits normal placental angiogenesis and can 
reduce placental blood flow and nutrient transport (9, 17).   
Hypoxia occurs when oxygen availability does not match the demand of the 
surrounding tissue (18).  In the presence of a hypoxic environment, cells activate the 
hypoxia inducible factor (HIF) signaling cascade which coordinates the expression of 
genes and ensures adaptation (18-20).  The primary targets of the HIF signaling cascade 
are the transcription factors HIF1a and ARNT.  Under normoxic conditions, HIF1a is 
rapidly hydroxlyated resulting in its degradation.  However, when oxygen levels are 
decreased, HIF1a hydroxylation is reduced allowing for its translocation to the nucleus 
where it dimerizes with ARNT.  This complex then binds to and induces the transcription 
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of genes (vascular endothelial growth factor A (VEGFA), glycolytic enzymes and 
inducible nitric oxide synthetase) which contain hypoxia responsive elements in their 
promoter region leading to their increased expression (21-23).   
When there is an increase in the level of hypoxia, an increase in oxidative stress 
usually arises as well (24, 25).  The generation of oxidative stress occurs due to an 
increase in reactive oxygen species (ROS) (26, 27); however, antioxidants like 
glutathione peroxidase (Gpx1) and superoxide dismutase (Sod) work to defend the body 
against their generation.  Conversely, xanthine oxidase, which is stimulated by hypoxia, 
promotes the production of ROS.  ROS can damage different biological targets such as 
lipids, DNA, carbohydrates and proteins which compromise cell function and can alter 
the transport of nutrients through the placenta (27, 28).   
Another important function of the placenta is regulating glucocorticoid 
availability to the embryo and fetus.  At the end of gestation, glucocorticoids are essential 
for the development and maturation of fetal organs (e.g. lung, thymus, gastrointestinal 
tract, heart, liver, and kidneys) (29-33).  Physiological glucocorticoids (cortisol in 
humans, corticosterone in rats and mice) are synthesized throughout pregnancy by the 
maternal adrenal cortex (34) and once produced, are able to be transported from the 
mother, through the placenta, to the developing fetus.  In the placenta, there are two 
enzymes, 11β hydroxysteroid dehydrogenase type 1 (Hsd11b1) and type 2 (Hsd11b2) 
which regulate the amount of maternal glucocorticoids that reach the fetus.  The enzyme 
Hsd11b1 catalyzes the conversion of cortisone (11-dehydrocorticosterone (11-DHC) in 
mice) to corticosterone/cortisol (35) while Hsd11b2 converts corticosterone/cortisol to 
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11-DHC/cortisone.  The expression of Hsd11b2 is regulated by oxygen (12, 36) and 
Mericq et al. (37) showed that Hsd11b2 enzyme activity in the placenta to be seven- to 
eightfold higher compared with the activity of Hsd11b1.  These data suggest that the 
primary role of the placenta is to convert glucocorticoids to their inactive form and limit 
fetal exposure of glucocorticoids until the end of the gestation.  There is evidence that 
glucocorticoid metabolism in the placenta may be altered due to a maternal obesity 
resulting in altered differentiation of the developing fetus (38). 
While there is evidence that maternal obesity negatively effects placental 
development and function, it is unclear if maternal obesity increases hypoxia and 
oxidative stress or alters glucocorticoid metabolism in the placenta.  In the current study, 
we use a Lethal Yellow (LY) obese mouse model to identify the impact of maternal 
obesity on markers of placental hypoxia, oxidative stress and glucocorticoid metabolism.  
Previously, we characterized LY mice  and showed that they over eat and have an altered 
hormone profile similar to that of obese humans (39).  Using this LY mouse model of 
obesity we have discovered differences in the placenta due to a maternal obese 
environment that may impact placental function and nutrient transport. 
MATERIALS AND METHODS 
Animal Model:  Founder B6 (C57BL/6 a/a) and LY (C57BL/6 Ay/a) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME).  Fertile, male B6 mice were 
mated with aged-matched (17 week old) B6 or LY female littermates.  Twelve days after 
visual confirmation of a vaginal plug (i.e., 12.5 dpc), B6 (n = 7) and LY (n = 12) dams 
were euthanized and maternal weights were determined.  Viable embryos and their 
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corresponding placenta were collected and wet weights were determined.  All of the 
placentas were flash frozen for RNA and protein extraction whereas half of the embryos 
from each litter were flash frozen for RNA and protein extraction.  All animal 
experiments were approved by the University of Nebraska-Lincoln Institutional Animal 
Care and Use Committee. 
Reverse transcription:  Whole placenta and whole embryo RNA was isolated 
using Tri-Reagent (Invitrogen, Carlsbad, CA).  RNA (5 μg) from each individual sample 
was treated with DNase I (Promega, Madison, WI) and reverse transcribed using random 
hexamer primers (Roche Diagnostics, Indianapolis, IN) and Moloney Murine Leukemia 
Virus reverse transcriptase (Promega) according to manufacturer’s instructions. 
Quantitative, real-time PCR (QPCR):  Forward and reverse primers for candidate 
genes and the housekeeping gene beta actin (Actb) (Table 3.1) were designed (Primer 
Express, Applied Biosystems, Foster City, CA) and synthesized (Integrated DNA 
Technologies, Coralville, IA).  Primers were tested empirically to determine the maximal 
concentration that produced specific amplification of the target sequence in the absence 
of primer dimers.   Quantitative PCR (QPCR) reactions were carried out using each 
primer set and equivalent amounts of cDNA from each sample as previously described 
(40).  QPCR amplification of Gapdh and 18s rRNA was carried out using an endogenous 
control kit (Applied Biosystems, Foster City, CA).  The relative abundance of the 
candidate mRNA in each sample was normalized using the most stably expressed 
housekeeping gene(s) (Gapdh, 18s, or Actb) which was determined using Normfinder 
(41).  Specifically, embryo candidate genes were normalized using the geometric mean of 
103 
 
18S rRNA and Gapdh mRNA abundance for each embryo sample while Gapdh mRNA 
abundance was used to normalize candidate genes for each placenta sample.  The 
resulting normalized data for each candidate mRNA was then compared to the mean 
normalized mRNA abundance in B6-derived placenta or embryos and expressed as a fold 
change.  
 
Table 3.1. Primer sequences for QPCR analysis. 
 
Protein Extraction: Whole placenta and whole embryo samples were 
homogenized in RIPA buffer (150 mM NaCl, 1 mM EDTA, 50mM Tris-HCl pH7.4, 1% 
NP-40, 0.25% Na-deoxycholate) containing phosphatase inhibitors (1 mM NaF and 1 
mM Na3VO4) and Complete Mini Protease Inhibitor Cocktail (Roche Diagnostics).  
Following homogenization, samples were sonicated and then centrifuged to separate cell 
debris from the supernatant which contained the soluble protein.  The protein 
concentration of each sample was determined using the Pierce BCA Protein Assay Kit 
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(Rockford, IL, USA).  Light absorbance was measured on a Spectra Max 250 plate reader 
(Molecular Devices, Sunnyvale, CA) at 562 nm.  
Western Blot Analyses:  Placenta protein samples were resolved by SDS-
polyacrylamide gel electrophoresis using a 4% stacking gel and 7% separating gel.  
Protein samples were loaded together with loading buffer (62.5 mM Tris-HCl pH 6.8, 
20% glycerol, 2% SDS and 5% β-mercaptoethanol) and electrophoresis carried out at 
constant voltage (100V) for 90 minutes.  The separated protein was transferred to 
Immobilon PVDF (Millipore, Billerica, MA).  Following transfer, the membranes were 
blocked with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 
0.1% (v/v) Tween 20)  for 1 hour with gentle shaking in order to block nonspecific 
proteins.  The blots were probed with primary antibody against Xanthine Oxidase (Santa 
Cruz Biotechnology, Santa Cruz, CA) diluted in 5% w/v BSA in 1XTBST overnight at 
4°C with gentle shaking.  Blots were then washed with 1X TBST and then incubated for 
1 hour with HRP-conjugated secondary antibody (Cell Signaling Technology, Danvers, 
MA) which was diluted with 5% nonfat dry milk in 1X TBST.  Blots were incubated with 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) for 5 min and exposed to 
autoradiograph film (Fisher Scientific, Fairlawn, IL).  After visualization of the protein, 
blots were stripped with Restore Western Blot Stripping Buffer (Thermo Scientific, 
Waltham, MA) at room temperature for 15 min.  Blots were then rinsed with 1X TBST 
and re-blocked with 5% milk in 1XTBST.  Next, they were incubated with primary 
antibody against β-Actin (Cell Signaling Technology, Danvers, MA) overnight at 4°C 
with gentle shaking.  Total protein was exposed and visualized as described above.  The 
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visualized total protein for β-Actin served as a loading control for each sample.  The 
autoradiograph images films were scanned and the density of the protein band was 
determined in Adobe Photoshop.  The density of the Xanthine Oxidase band was 
normalized to the density of the β-Actin band in each sample.  The normalized abundance 
of Xanthine Oxidase protein in LY samples was subsequently compared to the B6 control 
samples to determine the fold-change in the LY samples. 
Xanthine Oxidase Assay:  Placenta and embryo protein samples were analyzed for 
superoxide production using the Amplex® Red Xanthine Oxidase Assay Kit (Molecular 
Probes, Eugene, OR) according to manufacturer instructions with hypoxanthine as the 
substrate.  H2O2 was used as a positive control and reaction buffer without sample was 
used as a negative control.  After 30 minutes of incubation at 37°C, absorbance was read 
on a Spectra Max 250 plate reader (Molecular Devices, Sunnyvale, CA) at 560 nm.  
Hypoxanthine supplied in the kit was used as a standard and final sample concentrations 
were calculated based on the standard curve.   
Statistical Analyses:  All statistical analyses were carried out using GraphPad 
Prism 5.0 (GraphPad Software, La Jolla, CA).  Statistically significant differences in 
weights, mRNA abundance, protein expression or protein activity between B6 and LY 
dams or B6- and LY-derived embryos or placentas (P < 0.05) were determined using the 
Student’s t-test.   
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RESULTS 
Maternal Obesity Reduces Placental Weight and the Ratio of Embryo to Placental 
Weight:  We have previously demonstrated that the obese phenotype of LY females 
includes a significant increase in total body weight.  However, embryos from LY dams 
exhibit decreased mid-gestational embryonic weight (39).  Given that the placenta serves 
as a critical interface between the dam and fetus (5), the effect of maternal obesity on 
placental weight was examined.  Placenta weight was significantly reduced (P < 0.0001) 
when collected from a LY compared to a B6 dam (Chapter II, Figure 2.6A).  
Furthermore, there was a 12% decrease (P < 0.05) in the ratio of embryo to placenta 
weight when collected from LY dams (Chapter II, Figure 2.6A) which is indicative of 
reduced placental function and may explain the reductions of embryo weight and 
developmental delay previously identified (39).     
LY-Derived Placenta Display Mild Hypoxia and Altered Vasculature:  To 
determine how the molecular phenotype of the placenta was affected by maternal obesity, 
changes in the mRNA abundance of hypoxia candidate genes Hif1a and Arnt were 
measured.  Interestingly, Hif1a mRNA abundance was increased 20% (1.25-fold, P < 
0.06) in the placenta from LY mothers compared to B6 mothers (Chapter II, Figure 2.6B) 
suggesting hypoxemia (mild hypoxia) (42).  Since decreased oxygen levels results in the 
compensatory expression of vascular markers, we examined the mRNA abundance of 
vasculature markers Pecam1, Vcam1, Vegfa_164 and Vegfa_165b which are essential in 
the development of placental vasculature (23).  Pecam1 was significantly increased 
(1.34-fold, P < 0.05) in LY-derived placenta (Chapter II, Figure 2.6C); although none of 
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the other mRNAs showed significant changes in abundance (Chapter II, Figure 2.6C; data 
not shown for VEGFA_165b). 
Placental Hypoxemia Negatively Impacts Embryonic Vasculature:  Placental 
vascular development ensures for the proper exchange of nutrients exchange between the 
mother and fetus.  If a hypoxic environment in the placenta is altering its vasculature 
development, nutrient transfer may be decreased and negatively impact vascular 
development in the embryo.  Thus, we examined the expression of the vascular markers 
Vegfa_164 and Vegfa_165b in the mid-gestation embryos to discover if embryo vascular 
development is impaired.  We found a significant decrease (1.79-fold, P < 0.004) in 
Vegfa_164 and a tendency (1.59-fold, P < 0.10) for Vegfa_165b to be decreased in LY-
derived embryos (Figure 3.1).   
 
Figure 3.1. Vasculature Markers in Whole Embryos from LY Dams are Decreased.  QPCR 
analysis of the vasculature markers Vegfa_164 and Vegfa_165b was carried out.  The normalized, 
relative abundance of each gene from embryos from LY dams (yellow bars, n=10) was compared 
to the mean, normalized relative abundance of each gene from embryos from B6 dams (black 
bars, n=10) and the data shown as a fold change (mean ± SEM).  The data was tested for 
statistical significance (P < 0.1, † and P < 0.01, **). 
 
Maternal Obesity does not Induce Oxidative Stress in the Placenta of our LY 
Mouse Model:  It has been documented that hypoxia increases placental oxidative stress 
(25, 43).  Therefore, we examined several markers in B6- and LY-derived placenta 
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which, when their expression is altered, results in the development of oxidative stress.  
First, changes in the mRNA abundance of the antioxidant and superoxide dismutase 
genes Gpx1, Sod1 and Sod2 were measured.  While there was no difference in Sod1 or 
Sod2 expression, there was a tendency for the antioxidant Gpx1 to be decreased (1.14- 
fold, P < 0.09) in placenta from LY mothers (Figure 3.2A).  Next, we looked at the 
 
Figure 3.2.  LY-Derived Placenta Exhibit Mild Oxidative Stress Compared to B6-Derived 
Placenta.  QPCR analysis of the oxidative stress primers (A) Gpx1, Sod1 and Sod2 was carried 
out.  The normalized, relative abundance of each gene from placenta from LY dams (yellow bars, 
n=14) was compared to the mean, normalized relative abundance of each gene from placenta 
from B6 dams (black bars, n=12) and the data shown as a fold change (mean ± SEM).  (B) 
Western blot analysis was carried out using antibodies against Xanthine Oxidase.  Total β-Actin 
was subsequently probed and served as a loading control.  Semi-quantitative analysis of band 
density between LY (yellow bar, n=7) and B6-derived (black bar, n=8) placenta was calculated 
and shown as a fold change.  (C) Xanthine Oxidase activity in the placenta was measured using 
an Amplex Red Xanthine Oxidase Assay Kit and activity level is displayed between LY dams 
(yellow bar, n=16) and B6 dams (black bar, n=16).  The data was tested for statistical significance 
(P < 0.1, †). 
 
activity of the xanthine oxidase pathway which is one mechanism by which ROS is 
generated.  We found no difference in either the concentration or the activity of xanthine 
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oxidase in the placenta from B6- and LY-derived placenta (Figure 3.2B, C).  In addition 
to the placenta, we also examined these markers of oxidative stress in the embryos of B6 
and LY dams.  There were no differences in the mRNA abundance of Gpx1, Sod1 and 
Sod2 between B6- and LY-derived embryos (Figure 3.3A).  Likewise, we found no 
difference in xanthine oxidase activity in B6- compared to LY-derived embryos (Figure 
3.3B). 
 
Figure 3.3. LY-Derived Embryos Show No Signs of Oxidative Stress.  QPCR analysis of the 
oxidative stress primers (A) Gpx1, Sod1 and Sod2 was carried out.  The normalized, relative 
abundance of each gene from embryos from LY dams (yellow bars, n=10) was compared to the 
mean, normalized relative abundance of each gene from embryos from B6 dams (black bars, 
n=10) and the data shown as a fold change (mean ± SEM).  (B) Xanthine Oxidase activity in the 
embryos was measured using an Amplex Red Xanthine Oxidase Assay Kit and activity level is 
displayed between LY dams (yellow bar, n=16) and B6 dams (black bar, n=12).   
 
Maternal Obesity Results in Placenta with Alterations in Glucocorticoid 
Regulation:  In addition to oxidative stress, hypoxia also regulates placental 
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glucocorticoid metabolism; specifically, the enzymes Hsd11b1 and Hsd11b2 (responsible 
for the conversion of active-corticosterone/cortisol and inactive-11-DHC/cortisone) 
levels (44).   In order to determine if these enzymes were impacted in placenta collected 
from obese or lean dams, mRNA abundance was determined using primers specific for 
Hsd11b1 and Hsd11b2.  While there was no difference in Hsd11b1 mRNA levels, we 
found a 1.59 fold (P < 0.03) decrease in Hsd11b2 mRNA levels in placenta from LY 
compared to B6 mothers (Chapter II, Figure 2.6D).   
DISCUSSION 
Other studies have demonstrated that maternal obesity causes reduced 
angiogenesis and nutrient transport but the mechanisms are unclear.  In the current study, 
embryo weight (39), placenta weight and ratio were decreased (Figure 3.1), indicating 
potential abnormalities in placenta development and/or function.  The decrease in 
placenta and embryo weight (39) at mid-gestation is consistent with other rodent models 
of maternal obesity or gestational diabetes (45-47).  However, the exact role of the 
placenta in altered nutrient transfer and fetal growth restriction is unknown.   
Based on in vivo studies in human, sheep and rats, excessive exposure to a 
hypoxic environment can be detrimental to development by resulting in the inadequate 
perfusion of the placenta resulting in fetal growth restriction (12, 48).  Similarly, 
decreased placental function and nutrient transport has been found to result in a chronic 
state of fetal hypoxemia (49).  When looking at the impact of maternal obesity as 
opposed to induced hypoxia on the placenta we found a trend for increased HIF1a (Figure 
3.2) in placenta from an obese environment suggesting modest hypoxemia.  Hypoxia 
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causes increased expression of genes which contain the hypoxia response element in their 
promotor region (21-23).  Knowing this, additional evidence of mild hypoxemia in the 
placenta is the increased expression of Pecam1 (Figure 3.2B).   
While we found no change in VEGFA isoform expression in the placenta of LY 
compared to B6 dams (Figure 3.2), we found decreased or a tendency for decreased 
expression of the major angiogenic and anti-angiogenic isoforms (Figure 3.3) in LY-
derived compared to B6-derived embryos.  Mild hypoxemia in the placenta will alter its 
function and nutrient transport which plays a direct role in fetal programming, 
specifically modifications in embryonic vascular development which ultimately leads to 
cardiovascular or metabolic disease later in adult life (50). 
Alterations in the placental ROS/antioxidant balance due to maternal obesity can 
also affect placental function and nutrient transport and result in congenital irregularities 
or embryonic death (51).  Barrington et al. (52) found that women with low 
concentrations of serum selenium, the transition metal embedded within GPX, display 
increased placental oxidative stress and experience a higher rate of early pregnancy 
failure.  In our model of maternal obesity, there was no evidence of oxidative stress in the 
placenta or embryo using the markers selected for this study.  However, while Sod1 and 
Sod2 mRNA abundance was not different and xanthine oxidase protein and enzyme 
activity levels were not different between LY and B6 dams (Figure 3.4), there are other 
pathways which play a role in the synthesis of ROS that we did not examine.  These 
pathways that are known to increase H2O2 include NADPH oxidase, lipid peroxides, 
substrates of monoamine oxidases, isoprostanes and peroxisomal proliferators (53, 54).  
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Glucocorticoid regulation in the placenta is crucial to limit transport of maternal 
cortisol in the fetus (55).  Excessive exposure to glucocorticoids in utero can lead to 
altered maturation of organs as well as fetal growth restriction (32).  In humans, 
mutations in the Hsd11b2 gene reduces Hsd11b2 activity which leads to an increase in 
fetal corticosterone/cortisol levels and fetal growth restriction (34).  Likewise, exposure 
of rat fetuses to dexamethasone, a synthetic glucocorticoid, during the second half of 
gestation (12-22 dpc) resulted in reduced placenta and fetal weight and a decreased fetal-
to-placenta weight ratio (56).  The knockdown of the glucocorticoid receptor during early 
embryogenesis has also been found to reduce embryo length (57).  Together, these data 
indicate that an important function of the placenta is to regulate embryo exposure to 
active glucorticoids and the expression of Hsd11b2 is critical for this function.  Data in 
our current study indicates that maternal obesity decreases Hsd11b2 mRNA abundance 
(Figure 3.6).  Interestingly, hypoxia decreases placental Hsd11b2 levels (44, 58) while an 
increase in oxygen levels up-regulates glucocorticoid metabolism through Hsd11b2 
activation.  This suggests that the chronic, modest hypoxemia in the placenta of LY dams 
may result in altered glucocorticoid metabolism and increased exposure of these embryos 
to corticosterone.   
All in all, we have presented evidence that maternal obesity increases placental 
hypoxemia and decreases placental regulation of glucocorticoid metabolism.  These 
alterations in the molecular function of the placenta may represent plausible mechanisms 
for altered vascular development and growth of the embryos from obese dams.   
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APPENDIX A 
Effect of Maternal Obesity on Body Weight, Percent Body Fat, Reproductive Organ 
Weights, and Skeletal Muscle Molecular Phenotypes of Male and Female Offspring  
Kristin A. Norwood and Jennifer R. Wood 
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, NE 
 
INTRODUCTION 
Obesity worldwide is a rising epidemic which exists at a prevalence of 15–20% of 
the total population (1).  Over the past 20-30 years, the rate of overweight or obesity in 
the USA has increased from 15 to 33% in adults and has experienced similar increases in 
children and adolescents (2).  With the rise in the incidence of obesity it is now 
considered a significant public health problem which contributes 2-7 % of the total health 
care costs in the USA (1).  Obesity combined with pregnancy has been found to lead to 
an increase in maternal circulating lipids resulting in a pronounced effect on the growth 
and development of their conceptus (3).  Maternal obesity has been shown to increase the 
lifetime risk of obesity in offspring as well as lead to metabolic syndrome in childhood 
and adolescence (4-6).   
The correlation between maternal obesity and abnormalities in fetal 
growth/development has led to the establishment of a developmental overnutrition 
hypothesis which proposes that increased fuel supply to the fetus due to maternal 
overnutrition leads to permanent changes in offspring metabolism and growth (7-9).  
Other studies have established a correlation between maternal obesity and abnormalities 
in organ and whole body development. For example, studies have found increased 
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pancreas weight with enhanced early β–cell maturation (10-13), increases in triglyceride 
levels (14), increased liver weight leading to the development of nonalcoholic fatty liver 
disease (11, 14, 15), increased perirenal body fat weight or percent body fat (11, 12, 16, 
17) and only select studies have found an increase in heart weight (11, 13).  One study 
looked at gender differences and found liver weights to be increased in male offspring but 
not in female offspring while both males and females exhibit decreased muscle and 
increased fat pad weight when developed in an obese dam (16).   
While maternal obesity impacts multiple organ systems, how it is impacting 
skeletal muscle development is of particular importance given that muscle is a major 
metabolic organ and directly contributes to the development of obesity.  Several studies 
have looked at the effects of an altered maternal diet on embryonic muscle growth.  
These studies that have found IUGR fetuses to display a reduction in muscle mass (16, 
18), which may be due to maternal overnutrition interfering with myotube formation (19, 
20).  The pre-adipocyte marker, peroxisome proliferator-activated receptor gamma 
(PPARG) is expressed in skeletal muscle and its expression is higher in the skeletal 
muscle of offspring from obese dams indicating increased intramuscular adiposity in 
these offspring (20, 21).  Regulation of adult muscle mass is a complex process that is 
controlled by the transcription factor, PAX7, which drives the expression of myogenic 
factors (myogenic factor-5 (Myf5), myogenic differentiation 1 (MyoD), myogenin 
(Myog), and desmin (Des)) to promote the differentiation of proliferating muscle 
progenitor cells into myocytes and ultimately mature muscle fibers (22-26).  The 
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regulation of these genes is imperative for proper adult muscle regeneration, but how 
these genes are altered in the adult offspring of obese mothers has not been examined.   
Due to the rising incidence in obesity, many animal models have been used to 
determine the impact maternal obesity is playing on life-long offspring outcomes.  For 
example, prenatal overfeeding in the rat, mouse, and sheep leads to altered appetite 
regulation in the postnatal offspring (16, 27, 28) which is tied to increased postnatal 
weight gain and development of obesity.  These studies show that a maternal obese 
environment alters the development of their offspring resulting in altered organ 
development and body growth.  It is unknown if prenatal exposure to an obese 
environment coupled with postnatal stimulus for increased food intake has a synergistic 
effect on the morphology and/or function of specific organs.     
MATERIALS AND METHODS 
Animal Model:  Founder B6 (C57BL/6, a/a) and LY (C57BL/6, Ay/a) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME).  Fertile, female B6 mice were 
mated with LY male littermates (B6-LY) or female LY mice were mated with male B6 
littermates (LY-B6).  Following a natural birth, animals were weaned at 3 weeks, housed 
with 1 to 4 mice per cage, and provided ad libitum access to water and normal rodent 
chow.  At 12 weeks of age, both male and female offspring were euthanized, weighed 
and subjected to dual-energy X-ray absorptiometry (DEXA) using the Lunar PIXImus 
Densitometer (GE Medical Systems, Fitchburg, WI).  Following the DEXA scan, organs 
were removed from males (gastrocnemius skeletal muscle, liver, kidneys, adrenals, testis, 
seminal vesicles, epididymis and prostate) and females (gastrocnemius skeletal muscle, 
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kidneys, liver, ovaries and uterus) and their wet-weights were determined.  All organ 
weights were normalized to the total lean tissue mass of the animal.  The gastrocnemius 
skeletal muscle was flash frozen for RNA extraction.  In addition, B6 females were mated 
with fertile B6 males (B6-B6) and male offspring were collected at twelve weeks of age 
for body weight and DEXA analysis.  All animal experiments were approved by the 
University of Nebraska-Lincoln Institutional Animal Care and Use Committee. 
Reverse Transcription:  Gastrocnemius skeletal muscle RNA was isolated using 
the RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA).  RNA (1 μg) from each 
individual sample was treated with DNase I (Promega, Madison, WI) and reverse 
transcribed using random hexamer primers (Roche Diagnostics, Indianapolis, IN) and 
Moloney Murine Leukemia Virus reverse transcriptase (Promega) according to 
manufacturer’s instructions. 
Quantitative, Real-Time PCR (QPCR):  Forward and reverse primers for 
candidate genes and the housekeeping gene β-actin (Actb) (Table A.1) were designed 
(Primer Express, Applied Biosystems, Foster City, CA) and synthesized (Integrated DNA 
Technologies, Coralville, IA).  Primers were tested empirically to determine the maximal 
concentration that produced specific amplification of the target sequence in the absence 
of primer dimers.  Quantitative PCR (QPCR) reactions were carried out using each 
primer set and equivalent amounts of cDNA from each sample as previously described 
(29).  QPCR amplification of Gapdh and 18s rRNA was carried out using an endogenous 
control kit (Applied Biosystems, Foster City, CA).  The relative abundance of the 
candidate mRNA in each sample was normalized using the most stably expressed 
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housekeeping gene(s) (Gapdh, 18s, or Actb) which was determined using Normfinder 
(30).  Specifically, muscle candidate genes were normalized using the geometric mean of 
Actb and Gapdh mRNA abundance for each male or female muscle sample.  The 
resulting normalized data for each candidate mRNA was then compared to the mean 
normalized mRNA abundance in B6 offspring derived in a B6 dam and expressed as a 
fold change.  
 
Table A.1. Primer Sequences for QPCR Analysis 
 
Statistical Analyses:  All statistical analyses were carried out using GraphPad 
Prism 5.0 (GraphPad Software, La Jolla, CA).  Differences between male and female B6 
and LY offspring body weights, percent fat, total tissue mass, organ weights and mRNA 
abundance from either a B6 dam and LY sire or a LY dam and B6 sire were determined 
using one-way ANOVA and Bonferroni post-test.  If no difference was found between 
offspring from the same dam, then statistically significant differences between all 
offspring from a B6 dam and LY sire was compared to all offspring from a LY dam and 
B6 sire (P < 0.05) using Student t-test.    
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RESULTS 
 Maternal Obese Environment Impacts Male Offspring Growth and Fat Mass 
Irrespective of Paternal Phenotype:  In order to compare the adult phenotypes of male 
offspring developed in a lean versus obese environment, twelve week old male mice were 
examined.  B6 and LY males from B6-LY and LY-B6 crosses were compared.  Also, in 
order to verify that there was no paternal obesity influence, B6 males from a B6-B6 cross 
were examined.  As expected, LY males from B6-LY crosses showed increased body 
weight (1.39-fold, P < 0.0001), a 51% increase (2-fold, P < 0.0001) in percent body fat 
and increased (1.11-fold, P < 0.01) in total lean tissue mass compared to B6 male 
offspring from a B6-LY cross (Figure A.1A).  In addition, B6 male offspring from a LY-
B6 cross display increased (1.15-fold, P < 0.05) total lean tissue mass compared to B6 
male offspring from a B6-LY cross.  However, we surprisingly found no differences in 
body weight, percent fat and total lean tissue mass when comparing the B6 and LY male 
offspring from a LY-B6 cross (Figure A.1A).  In order to validate that a sire effect was 
not occurring with our model, we examined the impact of paternal obesity on body 
weight, percent body fat, or total lean tissue mass of B6 male offspring from a B6-B6 
cross with B6 male offspring from a B6-LY cross.  This comparison showed no 
difference in body weight, percent fat or total lean tissue mass (Figure A.1B) indicating 
no effect of paternal obesity on offspring phenotypes.  Together, this data shows that 
regardless of the sire phenotype, male B6 offspring from a B6-LY cross are significantly 
smaller and exhibit decreased body fat and total tissue mass compared to age-matched 
LY littermates. 
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Figure A.1.  Male LY Offspring from B6 Dams Display Increased Body, Fat and Total Lean 
Tissue Mass.  (A) Male offspring from B6 dams and LY sires (B6, dark grey bar, n=13; LY, light 
yellow bar, n=7) and from LY dams and B6 sires (B6, light grey bar, n=2; LY, dark yellow bar, 
n=4) were collected at 12 weeks of age.  Body weight was calculated and percent body fat and 
total lean tissue mass were determined via DEXA scan (mean ± SEM).  (B) For each comparison, 
male B6 offspring from a B6 dam and B6 sire (black bar, n=4 or 8) were compared to B6 
offspring from a B6 dam and LY sire (dark grey bar, n=13) to justify our control (dark grey bar).  
Statistically significant differences (P < 0.05, *; P < 0.01, **; P < 0.0001, ****) were determined 
using one-way ANOVA. 
 
 Male Organ Weights are Altered Based on their In Utero Maternal Environment:  
To determine if maternal obesity affects the growth of individual organs irrespective of 
total lean body mass, we next compared the weights of various organs between B6-LY 
and LY-B6 derived 12-week old offspring.  Gastrocnemius skeletal muscle (1.14-fold, P 
< 0.001) and kidney weight ratios (1.11-fold, P < 0.01) were decreased in LY compared 
to B6 offspring from a B6-LY cross (Figure A.2A).  The weight ratio for kidneys 
between B6 male offspring from a LY dam were increased (1.27-fold, P < 0.05) 
compared to B6 males from a B6 dam.  Likewise, we found an increase (1.15-fold, P < 
0.01) in the kidney weight ratio between LY male offspring from a LY dam compared to 
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a B6 dam.  Also, the testis (1.19-fold, P < 0.01) and epididymis (1.17-fold, P < 0.05) 
were significantly smaller in LY compared to B6 offspring from a B6-LY cross (Figure 
A.2B).  Due to the fact that there was no difference in adrenal and prostate weights 
between LY and B6 offspring from B6 dams or from LY dams, we grouped the weights 
of the adrenals from B6-LY and LY-B6 crosses regardless of the offspring’s phenotype.  
We found that both the adrenal glands (1.79-fold, P < 0.01) as well as the prostate (1.19-
fold, P < 0.10) from offspring developed from a LY-B6 cross were heavier than offspring 
from a B6-LY cross (Figure A.2A).   
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Figure A.2.  Organ Growth Differs in Male Offspring from B6 Dams and LY Dams.  (A, B) 
Male offspring from B6 dams (B6, dark grey bar, n=13; LY, light yellow bar, n=7) and LY dams 
(B6, light grey bar, n=2; LY, dark yellow bar, n=4) were euthanized and organs were removed.  
All organ weights were normalized to their corresponding total lean tissue mass (mean ± SEM) 
and statistically significant differences (P < 0.10, †; P < 0.05, *; P < 0.01, **; P < 0.001, ***) 
and tendencies were determined using one-way ANOVA.  If there were no differences between 
male offspring from the same dam a Students t-test was used for the combination of male 
offspring from a B6 dam compared to male offspring from a LY dam. 
126 
 
 Dependent on Maternal Weight, Adult Male Offspring Skeletal Muscle Display 
Differences in mRNA Expression:  The proper differentiation of muscle progenitor cells is 
needed for muscle to develop normally.  Thus, we examined the myogenic markers Pax7, 
Myod1, Myf5, Myog and Des in whole gastrocnemius skeletal muscle.  Due to low 
sample size, we grouped all muscle samples from offspring developed from a B6-LY  
 
Figure A.3.  Muscle Function in Male Offspring is Altered.  (A, B) QPCR analysis of Pax7, 
Myod1, Myf5, Myog, Des, Pparg, Igf2 and Slc2a4 was carried out.  The normalized, relative 
abundance of each gene from male B6 offspring derived in B6 dam (dark grey bar, n=5) was 
compared to the mean, normalized relative abundance of each gene from LY offspring derived in 
a B6 dam (light yellow bar, n=5), B6 offspring derived in a LY dam (light grey bar, n=1) or LY 
offspring derived in a LY dam (dark yellow bar, n=3) with the data shown as a fold change (mean 
± SEM).  Statistically significant differences (P < 0.1, †; P < 0.01, **) were determined using the 
Students t-test for the combination of male offspring from a B6 dam compared to male offspring 
from a LY dam. 
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cross and from a LY-B6 cross.  We found a tendency (1.22-fold, P < 0.08) for an increase 
in Myod1 expression in skeletal muscle from a LY-B6 cross compared to muscle 
developed from a B6-LY cross (Figure A.3A).  We also examined other markers that 
impact skeletal muscle metabolism (Pparg, Igf2 and Slc2a4) and found Slc2a4 expression 
to be 21% decreased (1.27-fold, P < 0.001) in muscle developed from a LY-B6 cross 
compared to a B6-LY cross (Figure A.3B). 
 Female Offspring Show a Similar Growth Pattern as Their Male Littermates: We 
found the female LY compared to B6 offspring from a B6-LY cross to exhibit a 27% 
increase (1.38-fold, P < 0.0001) in body weight (Figure A.4).  Similarly, there was a 
significant increase (P < 0.0001) in percent body fat (2.13-fold, 53%) in LY offspring 
from a B6-LY cross compared to B6 littermates (Figure A.4).  In contrast to the male 
offspring, we found a 40% increase (1.67-fold, P < 0.01) in percent body fat in LY 
compared to B6 offspring from a LY-B6 cross.  However, while we found differences in 
total lean tissue mass in male offspring, no differences were seen in female offspring. 
 
Figure A.4.  Female Offspring from B6 and LY Dams Exhibit Differing Body Growth 
Depending on their Phenotype.  Female offspring from B6 dams and LY sires (B6, dark grey 
bar, n=10; LY, light yellow bar, n=9) and from LY dams and B6 sires (B6, light grey bar, n=2; 
LY, dark yellow bar, n=4) were collected at 12 weeks of age.  Body weight was calculated and 
percent body fat and total lean tissue mass were determined via DEXA scan (mean ± SEM).  
Statistically significant differences (P < 0.01, **; P < 0.0001, ****) were determined using one-
way ANOVA. 
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LY Female Organ Weights are Decreased Compared to B6 Littermates 
Regardless of Dam Phenotype:  Female kidney weight ratio was increased (1.08-fold, P < 
0.10) in B6 and LY female offspring from a LY-B6 cross compared to B6 and LY 
offspring from a B6-LY cross (Figure A.5A, B).  The liver showed an increased weight 
ratio between LY and B6 offspring from a LY dam (1.30-fold, P < 0.05) as well as when 
from a B6 dam (1.21-fold, P < 0.001).  We also determined the uterus to be significantly 
smaller (1.23-fold, P < 0.001) in LY compared to B6 littermates from a B6-LY cross 
(Figure A.5B).  Interestingly, when the ovaries were grouped according to dam, we found 
a decrease (1.36-fold, P < 0.05) in weight ratio when developed from a LY-B6 cross 
compared to a B6-LY cross (Figure A.5B). 
 
Figure A.5.  Female Offspring Display Altered Organ Growth When From a B6 Compared 
to LY Dam.  (A, B) Female offspring from B6 dams (B6, dark grey bar, n=10; LY, light yellow 
bar, n=9) and LY dams (B6, light grey bar, n=2; LY, dark yellow bar, n=4) were euthanized and 
the gastrocnemius skeletal muscle, kidneys, liver, ovaries and uterus were removed.  All organ 
weights were normalized to their corresponding total lean tissue mass (mean ± SEM) and 
statistically significant differences (P < 0.10, †; P < 0.05, *; P < 0.001, ***) were determined 
using one-way ANOVA.  If there were no differences between female offspring from the same 
dam a Students t-test was used for the combination of female offspring from a B6 dam compared 
to female offspring from a LY dam. 
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Female Skeletal Muscle Myogenic Factors are Altered in LY-B6 Crosses:  The 
myogenic factors Pax7, Myod1, Myf5, Myog and Des were examined in female whole 
gastrocnemius skeletal muscle.  While no difference was found for Pax7, Myod1, or Des, 
we found a 27% reduction (1.37-fold, P < 0.05) for Myf5 and a 29% reduction (1.42-fold, 
P < 0.05) for Myog mRNA expression of offspring skeletal muscle from a LY-B6 cross  
 
Figure A.6.  Muscle mRNA Expression Differs in Female Offspring Skeletal Muscle.  (A, B) 
QPCR analysis of Pax7, Myod1, Myf5, Myog, Des, Pparg, Igf2 and Slc2a4 was carried out.  The 
normalized, relative abundance of each gene from female B6 offspring derived in B6 dam (dark 
grey bar, n=5) was compared to the mean, normalized relative abundance of each gene from LY 
offspring derived in a B6 dam (light yellow bar, n=5), B6 offspring derived in a LY dam (light 
grey bar, n=1) or LY offspring derived in a LY dam (dark yellow bar, n=3) with the data shown 
as a fold change (mean ± SEM).  Statistically significant differences (P < 0.05, *) were 
determined using the Students t-test for the combination of female offspring from B6 dams 
compared to female offspring from LY dams. 
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compared to a B6-LY cross (Figure A.6A).  We also examined other muscle markers 
(Pparg, Igf2 or Slc2a4) that impact muscle metabolism but failed to find any differences 
in gene expression between offspring from a B6-LY compared to LY-B6 cross (Figure 
A.6B). 
SUMMARY 
 The preliminary data collected in this study suggests that there are genetic 
alterations that are occurring in offspring reared in an obese compared to a normal weight 
environment.  However, the small sample size from each experimental group made it 
difficult to ascertain the statistical significance of these data.  We did, however, detect an 
environmental effect due to maternal obesity with the difference in kidney and ovary 
weights in female offspring where kidneys were increased and ovary were decreased in 
LY-B6 compared to B6-LY crosses (Figure A.5).  Additionally, male adrenal weights 
were significantly larger when developed from a LY-B6 compared to a B6-LY cross 
(Figure A.2A) and prostate weight ratio was increased in male offspring from a LY-B6 
compared to a B6-LY cross (Figure A.2B.  We also experienced some gender dependent 
differences in gastrocnemius skeletal muscle mRNA expression but it is not clear how 
these changes are affecting muscle signaling. 
We expected to see a synergistic effect when LY offspring were developed in a 
LY dam; however, we only experienced this effect in male kidneys.  The lack of a 
synergistic effect of prenatal and postnatal obesity on organ growth and development in 
LY derived from LY-B6 cross may be attributed to our low animal numbers, differences 
in the number of mice per cage and variations in litter size.  Also, our offspring are 12 
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weeks old which may be too early to see a dramatic phenotype.  Later time points may be 
needed in order to allow for more drastic effects to take form.  Altogether, further studies 
are needed that control for litter size, mice per cage, food intake and take into account the 
impact of paternal obesity in order to make valid conclusions as to the effect of maternal 
obesity on offspring development and organ function.  
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APPENDIX B 
Genes Involved in the Immediate Early Response and Epithelial-Mesenchymal 
Transition are Regulated by Adipocytokines in the Female Reproductive Tract. 
 
Zhufeng Yang, Kristin A. Norwood, Jacqueline E. Smith, Jill G. Kerl, and Jennifer R. 
Wood 
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, NE 
Molecular Reproduction & Development. 2012 Feb; 79(2): 128-137  
 
These results were performed and then combined with work done by Zhufeng Yang 
and others which was published in Molecular Reproduction & Development in 
2012. 
Epithelial-Mesenchymal Transition (EMT) mRNA Levels are Increased in the LY Uterus:   
The effect of an obese phenotype on the abundance of IE and EMT mRNAs in the whole 
uterus was subsequently determined by QPCR.  Uterus was collected 44 hours after eCG 
stimulation from 6, 12, or 24 week old LY and B6 females.  RNA was isolated from the 
whole uterus and QPCR was carried out using primers against cJun, cFos, cMyc, Snai1, 
Snai2, or Twist1 (Figure B.4).  There was no difference in cJun, cFos, or cMyc mRNA 
abundance in the uterus of LY compared to B6 at any age (Figure B.4A).  However, both 
cJun and cMyc mRNA levels were increased in 24 compared to 6 and 12 week-old LY 
and B6 females. Conversely, Snai1, Snai2, and Twist1 mRNA abundance was increased 
in the whole uterus of 6 week-old LY compared to age-matched B6 females (Figure 
B.4B).    Similar to cJun and cMyc, the mRNA abundance of Snai1 was also increased in 
24 week-old LY and B6 uterus compared to 6 and 12 week-old uterus.    
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  The differences in uterine Snai1, Snai2, and Twist1 mRNA levels between 6 
week-old LY and B6 females were correlated to increased circulating IGF-1 levels at this 
age (compare Figure B.3B and B.4B).  IGF-1 and IGF-1 binding proteins (IGFBPs) are 
also expressed in the murine uterus (1, 2).  Therefore, QPCR was carried out to identify 
differences in uterine levels of Igf1, Igfbp2, or Igfbp3 mRNAs between age-matched LY 
and B6 females (Figure B.4C).  While Igf1 and Igfbp2 mRNA levels were not different 
between LY and B6, Igfbp3 mRNA abundance was increased in uterus of 6 week-old LY 
compared to B6 females.  Furthermore, Igfbp3 tended to be increased in 24 week-old LY 
compared to B6 uterus.   
 
Figure B.4. Abundance of IE, EMT, and IGF family mRNAs in Uterus of Obese and 
Normal-Weight Females.  Total RNA was isolated from the whole uterus of 6, 12, or 24 week-
old B6 (black bars) or LY (white bars) females 44 h after eCG stimulation.  Quantitative, real-
time PCR was carried out using primers specific for (A) cJun, cFos, or cMyc; (B) Snai1, Snai2, or 
Twist1; or (C) Igf1, Igfbp2, or Igfbp3 as described in Figure 1.  Analysis of the resulting QPCR 
data was also carried out as described in Figure 1.   Statistically significant differences in fold 
change (P < 0.05) were determined using one-way ANOVA and Tukey-Kramer post-test and 
indicated by different letters. 
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